

Mariacristina Parravano, M.D.

curriculum vitae

**Associate Professor in Ophthalmology at Saint Camillus International University of Health Sciences-
UniCamillus**

**Researcher at IRCCS Fondazione Bietti, Rome, Italy
(2004-Present)**

Presidio Ospedaliero Britannico, Via di Santo Stefano Rotondo n 6,
Rome, Italy, 00184
(+39) 0684009442

Professional Appointments

Saint Camillus International University of Health Sciences-UniCamillus, Rome, Italy
2024-Associate Professor in Ophthalmology

IRCCS Fondazione Bietti, Rome, Italy
Head, Medical Retina Unit

Italian Ministry of Health
Research workflow Responsible of IRCCS-Fondazione Bietti Retina projects

Previous Professional Appointments

IRCCS-Fondazione Bietti, Rome, Italy
2004-Present Researcher in the Medical Retina Unit

***Complesso Ospedaliero S.Giovanni-Addolorata, IRCCS-Fondazione Bietti, Rome,
Italy***
2008-2017 Consultant in the Maculopathy Center

IRCCS-Fondazione Bietti, Rome, Italy
2015-Present Head of Medical Retina Unit

Italian Ministry of University

2017 Associate Professor, Ophthalmology

University of Rome Tor Vergata

Rome, Italy

Contract Professor Ophthalmology Residency: Retinal Pathologies

Policlinico A. Gemelli, Rome, Italy

Speaker II Level University Master in “Vitreoretinal pathologies: from the diagnosis to medical and surgical treatment”. “Medical Retina Course II” (3 hours). Title: WetAMD etiopathogenesis and diagnosis. 18 March 2011

Education

University of Campus BioMedico

Rome, Italy

1994-2000: M.D.

Postgraduate Training

University of Rome Tor Vergata

Rome, Italy

2001-2004: Resident in Ophthalmology

Moorfields Eye Hospital

London, UK

2004: Observer in Medical Retina Unit (Prof A. Bird)

IRCCS-Fondazione Bietti

Rome, Italy

2006-2007 Fellowship Medical Retina

Licensure

Italy

Unrestricted license to practice medicine and surgery (2001), and ophthalmology (2004)

GCP 9 Settembre 2022

Awards

1. Prize winner ARVO Travel Grant Fondazione GB Bietti per lo studio e la ricerca in Oftalmologia, 2003
2. Prize winner clinical research “Associazione Amici di Vanda” Givre Meeting, 2009.
3. Prize winner Fondi 5 per mille 2014 IRCCS-Fondazione Bietti project: “Studio del potenziale ruolo protettivo dell'enzima glutatione trasferasi nei confronti di fattori che inducono neurodegenerazione retinica ed analisi dell'effetto della variabilità glicemica su cellule gliali retiniche” 1/7/2016 al 31/12/2018.
4. Prize winner “Conto Capitale 2015” Italian Ministry of Health "Multimodal morpho-functional wide-field analysis for the neurovascular evaluation of high social impact neuro-retinal pathologies", 2015
5. Prize winner “LAZIOINNOVA” VALIDAZIONE DI UN NUOVO ANTICORPO MONOCLONALE MULTI-TARGETED PER IL TRATTAMENTO DI TUMORI E PATOLOGIE RETINICHE POLITERMAB. Apr 2021
6. Prize winner Conto capitale 2021 “Functional system for the study of the phenotype-gentotype correlation of the ereditary oculo pathologies by means high resolution imaging”.

Professional Memberships

Author and reviewer for systematic revision for Cochrane Eyes and Vision from 2009 al 2022

EVICR.net Diabetic Retinopathy and Vascular Diseases Expert Committee 2017-today

Member of the Esaso Faculty from 2016-today

Association for Research in Vision and Ophthalmology (ARVO)

Club Jules Gonin 3-6 Sept 2014

Macula Society 15 October 2020

American Academy of Ophthalmology (2008-2010)

European Retinal Specialists Society (EURETINA)

Italian Retina Society (SIR)- Steering Committee 2015-today

Società Italiana di Oftalmologia (SOI)

SISO Italian society

Meeting/Course Scientific Committee

1. Corso “Retinopatia Diabetica ed edema maculare: Cosa c’è di nuovo?” Roma 14 Ottobre 2017
2. Corso Imaging nella “Retinopatia Diabetica ed Edema Maculare Diabetico” Roma 26 Ottobre 2018
3. Corso ECM FAD Gennaio-Dicembre 2022 “Novità nella diagnostica multimodale e nella scelta terapeutica della degenerazione maculare legata all’età Responsabile Scientifico, IRCCS-Fondazione Bietti
4. Congresso VitReEx 11-13 Maggio 2023
5. Congresso Case Reports La Gestione dei Casi Complessi 2023 Roma 6 Maggio 2023
6. Retina Workshop Approccio diagnostico alla patologia retinica Bologna 10 Novembre 2023
7. Congresso Case Reports La Gestione dei Casi Complessi 2024 Roma 13 Aprile 2024

Principal Investigator (PI) / Co-Investigator in clinical trials (CoI) – (selected list)

Co-Investigator in the multicentric studies

1. A six-month, phase 3, multicenter, masked, randomized, sham-controlled trial (with six-month open label extension) to assess the safety and efficacy of 700 and 350 Dexamethasone Posterior segment Drug delivery System (DEXPSDDS) Applicator System in the treatment of patients with macular edema following central retinal vein occlusion or branch vein occlusion. (GENEVA)
2. A 3 year, phase 3, multicenter, masked, randomized, sham-controlled trial to

assess the safety and efficacy of 700 and 350 Dexamethasone Posterior Segment Drug delivery System (DEXPSDDS) Applicator System in the treatment of patients with diabetic macular edema. (MEAD)

3. A 12-month randomized, double-masked, controlled, multicenter, phase II study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with Lucentis™ versus Lucentis™ monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
4. A 12 Months Case Series open study to assess the safety and efficacy of intravitreal injection of Lucentis(Ranibizumab 0.5 mg) used in combination with Visudyne (Verteporfin PDT) in naive subjects with subfoveal CNV secondary to AMD.
5. A randomized, double masked , active controlled phase 3 study of the efficacy, safety and tolerability of repeated doses of intravitreal VEGF trap-Eye in subjects with neovascular age-related macular degeneration (AMD) (VIEW2).
6. A phase II prospective , randomised , multicentric diabetic macular edema dose ranging, comparison study evaluating the efficacy and safety of PF- 04523655 versus laser therapy (DEGAS).
7. A randomized, double-masked, sham-controlled phase 3 study of the efficacy, safety, and tolerability of repeated intravitreal administration of VEGF Trap-Eye in subjects with macular edema secondary to central retinal vein occlusion (CRVO) (GALILEO).
8. Macular edema Incidence/Severity Reduction with NEVANAC® Phase IIIb, prospective, multicenter, double-masked, randomized, parallel group, placebo controlled study.
9. Multicentric, phase 3b, randomized, single blind, controlled, 2 years follow up to evaluate the efficacy and safety of 0.5 mg ranibizumab treat and extend vs 0.5 mg ranibizumab as needed in patients with diabetic macular edema (RETAIN).
10. Multicentric, phase 3, randomized, double blind, active control, 12 months follow up to evaluate the efficacy and safety of 0.5 mg ranibizumab vs photodynamic therapy in myopic CNV.
11. A randomized, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macular edema (VIVID).
12. A 12-Month, Multicentre, Randomised, Parallel Group Study to Compare the

Efficacy and Safety of Ozurdex® Versus Lucentis® in Patients with Branch Retinal Vein Occlusion (COMO).

13. A multicenter, open-label, randomized study comparing the efficacy and safety of 700 µg Dexamethasone posterior segment drug delivery system (DEX PS DDS) to ranibizumab in patients with diabetic macular edema.
14. A non-interventional study in patients with diabetic macula edema (DME) with central involvement to assess the effectiveness of existing anti vascular endothelial growth factor (anti-VEGF) treatment regimens (POLARIS).
15. Prospective, randomized, multicentre, open label, phase II / III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) *versus* PRP in monotherapy in the treatment of subjects with high risk proliferative diabetic retinopathy. (PROTEUS).
16. A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV) (MINERVA). Novartis.
17. A 12 months, open-label, interventional, multicentre study to investigate the current criteria driving re-treatment with ranibizumab upon relapse in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia. Novartis.
18. A 12-month, phase IIIb, randomized, single-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in Treat and Extend regimen compared to Monthly regimen, in patients with neovascular age-related macular degeneration (TREND). Novartis.
19. A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista™ (Anti PDGF-B pegylated aptamer) administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal neovascular age-related macular degeneration (FOVISTA). Ophthotec.
20. A Collaborative Retrospective Trial on the Efficacy and Safety of intravitreal dexamethasone implant (Ozurdex) in patients with Diabetic Macular Edema (DME). THE EUROPEAN DME REGISTRAR STUDY (ARTES). Allergan.
21. A multicenter, single-arm, interventional Phase 4 study to evaluate a treat and extend regimen of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion (CENTERA)

22. Managing neovascular age related macular degeneration over 2 years with a treat and extend regimen of 2 mg intravitreal aflibercept-a randomized, open label, active controlled, parallel group phase IV/IIIb study (ARIES)
23. An open label, randomized, active controlled, parallel group, phase 3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neovascular age related macular degeneration (AZURE)
24. An observational study program to investigate the effectiveness of intravitreal Aflibercept in diabetic macular edema and/or macular edema secondary to retinal vein occlusion in a real world setting (AURIGA)
25. Evidence of Anti-VEGF use in real Life Experience-a A retrospective cohort study from secondary data source in Italy- chart Review (EAGLE)
26. A randomized,double-masked,placebo-controlled exploratory study to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of orally administered BI 1467335 for 12 weeks with a 12 weeks follow up period in patients with Non-Proliferative diabetic retinopathy without center-involved diabetic macular edema (ROBIN study)
27. A two-year, three-arm, randomized, double-masked,multicenter,phaseIII study assessing the efficacy and safety of Brolucizumab versus aflibercept in adult patients with visual impairment due to Diabetic Macular Edema (KESTREL) NOVARTIS
28. An eighteen-month, two-arm,randomized,double-masked,multicenter,phase III study assessing the efficacy and safety of Brolucizumab versus aflibercept in adult patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (RAPTOR) NOVARTIS
29. A Phase III, Multi-Center, Randomized, Double-Masked, ShamControlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (OAKS) APELLIS
30. A phase 3 multicenter, randomized, double-masked, sham-controlled clinical trial to asses the safety and efficacy of intravitreal administration of Zimura (complement CS inhibitor) in patients with geographic atrophy secondary to dry age-related macular degeneration. (ISEE2008) IVERIC-BIO
31. Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of Xlinked Retinitis Pigmentosa Associated with Variants in the RPGR gene (LUMEOS) MeiraGTx

32. Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema due to Retinal Vein Occlusion (QUASAR) BAYER

Principal Investigator in the multicentric studies

1. Safety and Efficacy of Abicipar Pegol in Patients with Neovascular Age-related Macular Degeneration (DARPin) (SEQUOIA). Allergan
2. A phase III, multicenter, randomized, double-masked, sham-controlled study of efficacy and safety of 10 mg lampalizumab intravitreal injections administered every 30 or 45 days to patients with Geographic atrophy secondary to age related macular degeneration. (CHROMA) ROCHE
3. Development of novel clinical endpoints for interventional clinical trials with a regulatory and patient access intention in patients with intermediate age-related macular degeneration (AMD)- (MACUSTAR) EVICR.net
4. A phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of RO6867461 in patients with Diabetic Macular Edema (YOSEMITE) ROCHE
5. A multicenter, double-masked, randomized, dose-ranging Trial to evaluate the efficacy and safety of Conbercept intravitreal injection in subjects with Neovascular age-Related Macular degeneration (PANDA) Chengdu Kanghong Pharmaceutical Industry Group Co., Ltd.
6. A phase III, multicenter, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety of Faricimab in patients with neovascular age related macular degeneration (TENAYA) ROCHE
7. Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of dementia – (RECOGNISED) Sponsor: Fundació Hospital Universitari Vall D’Hebron, VHIR. Horizon 2020
8. One Year, single arm, open label, multicenter, phase IV study using multimodal imaging to guide disease activity assessment through innovative early predictive anatomical biomarkers of fluid resolution in wAMD patients treated with brolicizumab-(IMAGINE) study. Novartis

9. A phase 2, randomized, multicenter study to assess the dose level of multiple THR-149 injections and to evaluate the efficacy and safety of THR-149 versus aflibercept for the treatment of diabetic macular edema (DME). (KALAHARI) OXURION
10. A multicenter, open-label extension study to evaluate the long-term safety and tolerability of Faricimab in patients with Diabetic macular edema (RHONE-X) ROCHE
11. A multicenter, open-label extension study to evaluate the long-term safety and tolerability of Faricimab in patients with neovascular age related macular degeneration (AVONELLE-X) ROCHE
12. A phase III, multicenter, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety of Faricimab in patients with macular edema secondary to central or hemiretinal vein occlusion. (COMINO) ROCHE
13. Patient experience and preference (PEP) study in nAMD and DME (PEP) ROCHE
14. A longitudinal, biomarker study of Anti-VEGF, to explore the relationship between aqueous humor composition and multimodal retinal imaging in neovascular age-related macular degeneration and diabetic macular edema. (LONGITUDE) ROCHE
15. Characterization of retinal disease progression in eyes with NPDR in diabetes Type 2 using non-invasive procedures (CHART) AIBILI
16. RWE study of anti-vegf therapies in neovascular age-related macular degeneration in Italy : adherence, needs, cost and effectiveness analysis: the radiance study. (RADIANCE) ROCHE
17. A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD) (COAST) OPTHEA
18. A Multicenter, Prospective Study Of The Progression Of Intermediate Age-Related Macular Degeneration (HONU) GENENTECH
19. Geographic Atrophy Long-Term Outcomes Study: an ambispective non-interventional study to describe the patient demographics, baseline characteristics,

and outcomes of patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in clinical practice. (GALTOS) APELLIS

20. A collaborative resource of Heidelberg multimodal imaging of intermediate AMD with and without early atrophy to study prediction of disease progression. (INTERCEPT) EVCRnet
21. A multi-country, post marketing observational study of DME patients with suboptimal response to anti-VEGF who are initiated with Dexamethazone intravitreal implant (DEX-I).(INITIATE) ABBVIE

Data and Safety Monitoring Board Clinical Trials Member

- PROTOCOL FYB201-C2015-01-P3 (EudraCT nr: 2015-001961-20): EFFICACY AND SAFETY OF THE BIOSIMILAR RANIBIZUMAB FYB201 IN COMPARISON TO LUCENTIS IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (COLUMBUS-AMD). SPONSOR BIOEQ.GmbH. 2016-2018
- A PHASE 3 RANDOMIZED, DOUBLE MASKED, MULTICENTER STUDY TO COMPARE THE EFFICACY AND SAFETY OF THE PROPOSED AFLIBERCEPT FYB203 BIOSIMILAR IN COMPARISON TO EYLEA® IN PATIENTS WITH NEOVASCULAR AGE RELATED MACULAR DEGENERATION (MAGELLAN AMD). EudraCT No 2019-003923-39. SPONSOR BIOEQ.GmbH. Ongoing

Editor in Chief, Associate Editor, Editorial Board Member for International Peer Reviewed Journal

- Expert Review of Ophthalmology

Scientific Reviewer for International Peer Reviewed Journal –

(selected list)

Acta Ophthalmologica

Acta Diabetologica

American Journal of Ophthalmology

British Journal of Ophthalmology
Clinical Ophthalmology
European Journal of Ophthalmology
IOVS
JAMA ophthalmology
Journal of Ocular Pharmacology and Therapeutics
Ophthalmic Research
Ophthalmologica
Ophthalmology
PLOS one
Retina
Retinal Cases & Brief Reports
TVST

Publications

Journal Articles (sort by publication date):

PUBMED link: <https://www.ncbi.nlm.nih.gov/pubmed/?term=parravano+m>

1. Manni G, Centofanti M, Sacchetti M, Oddone F, Bonini S, **Parravano M**, Bucci MG. Demographic and clinical factors associated with the development of Brimonidine tartrate 0.2% induced ocular allergy. *J Glaucoma*, April 2004,13(2):163-7. doi: 10.1097/00061198-200404000-00014. PMID: 15097264
2. Manni G, Centofanti M, **Parravano M**, Oddone F, Bucci MG. A six month randomized clinical trial comparing Bimatoprost 0.03% versus the association of Timolol 0.5% and Latanoprost 0.005% in glaucomatous patients. *Graefes Arch Clin Exp Ophthalmol* 2004 Sep;242(9):767-70. doi: 10.1007/s00417-004-0866-2. PMID: 15241611
3. Manni G, Centofanti M, Oddone F, **Parravano M**, Bucci MG. Interleukin-1 β tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free non selective beta-blockers. *Am J Ophthalmol* 2005 Jan;139(1):72-7. doi: 10.1016/j.ajo.2004.08.028. PMID: 15652830

4. Centofanti M, Oddone F, **Parravano M**, Gualdi L, Manni G. Corneal birefringence changes after laser assisted in situ keratomileusis and their influence on retinal nerve fibre layer thickness measurement by means of scanning laser polarimetry. *Br J Ophthalmol* 2005 Jun;89(6):689-93. doi: 10.1136/bjo.2004.054726. PMID: 15923503
5. Bucci MG, Parravano M, Balacco Gabrieli C, Pecori-Giraldi J, Librando A, [Paone E](#), Bores LD Pilot study to evaluate the efficacy and safety of pneumatic trabeculoplasty in glaucoma and ocular hypertension. *Eur J Ophthalmol* 2005 May-Jun;15(3):347-52. doi: 10.1177/112067210501500306. PMID: 15945003
6. **Parravano M**, Oddone F, Sampalmieri M, Gazzaniga D. Reliability of the IOLMaster in axial length evaluation in silicone oil-filled eyes. *Eye (Lond)* 2007 Jul;21(7):909-11. doi: 10.1038/sj.eye.6702452. Epub 2006 Jul 28. PMID: 16878120. [Epub ahead of print]
7. Ricci F, Missiroli F, **Parravano M**. Argon Laser Trabeculoplasty in Triamcinolone Acetonide induced ocular hypertension refractory to maximal medical treatment. *Eur J Ophthalmol*. 2006 Sep-Oct;16(5):756-7. doi: 10.1177/112067210601600516. PMID: 17061231
8. Orzalesi N, Rossetti L on behalf of the OPTIME Study Group (Osservatorio sulla Patologia glaucomatosa, Indagine Medico Epidemiologica), CONPROSO (Collegio Nazionale dei Professori Ordinari di Scienze Oftalmologiche). Vascular risk factors in glaucoma: the results of a national survey. *Graefes Arch Clin Exp Ophthalmol*. 2007 Jun;245(6):795-802. doi: 10.1007/s00417-006-0457-5. PMID: 17120006. Epub 2006 Nov 22.
9. Ferranini M, Vischini G, Staffolani E, Scaccia F, Miani N, **Parravano MC**, Louis MM, Splendiani G, Di Daniele N. Rheopheresis in vascular diseases. *Int J Artif Organs* 2007 Oct;30(10):923-9. doi: 10.1177/039139880703001010. PMID: 17992654
10. **Parravano M**, Oddone F, Mineo D, Centofanti M, Borboni P, Lauro R, Tanga L, Manni G. The role of Humphrey Matrix testing in the early diagnosis of retinopathy in type 1 diabetes. *Br J Ophthalmol*. 2008 Dec; 92(12):1656-60. doi: 10.1136/bjo.2008.143057. PMID: 18829632. Epub 2008 Oct 1.
11. Schiano Lomoriello D, **Parravano MC**, Chiaravalloti A, Varano M. Choroidal neovascularization in angioid streaks and pseudoxanthoma elasticum: 1 year follow-up. *Eur J Ophthalmol*. 2009 Jan-Feb;19(1):151-3. doi: 10.1177/112067210901900125. PMID: 19123166.

12. **Parravano M**, Oddone F, Tedeschi M, Lomoriello DS, Chiaravalloti A, Ripandelli G, Varano M. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration patients treated with ranibizumab. *Retina*. 2009 Mar; 29(3):329-34. doi: 10.1097/IAE.0b013e31819093e6. PMID: 19092732.
13. Varano M, Tedeschi M, Oddone F, Perillo L, Coppè AM, **Parravano M**. Microperimetric retinal changes in myopic choroidal neovascularization treated with intravitreal Ranibizumab. *Retina*. 2010 Mar;30(3):413-7. doi: 10.1097/IAE.0b013e3181bd2d23. PMID: 20010453
14. **Parravano M**, Oddone F, Tedeschi M, Lomoriello DS, Chiaravalloti A, Ripandelli G, Varano M. Microperimetry in neovascular age-related macular degeneration (AMD). Letter to the Editor. *Retina* 2009 29(10): 1549-50. doi: 10.1038/eye.2017.34 PMID: 28257134
15. **Parravano M**, Menchini F, Virgili G. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. *Cochrane Database Syst Rev* 2009 Oct 7:(4):CD007419. doi:10.1002/14651858.CD007419.pub2. PMID: 19821414
16. **Parravano M**, Oddone F, Tedeschi M, Chiaravalloti A, Perillo L, Boccassini B, Varano M. "Retinal functional changes measured by microperimetry in neovascular age related macular degeneration treated with ranibizumab: 24 months results". *Retina*. 2010 Jul-Aug;30(7):1017-24. doi: 10.1097/IAE.0b013e3181cfd3c6. PMID: 20224469
17. **Parravano M**, Oddone F, Boccassini B, Menchini F, Chiaravalloti A, Schiavone M, Varano M. Reproducibility of Macular Thickness Measurements Using Cirrus Spectral Domain Optical Coherence Tomography in Neovascular Age-Related Macular Degeneration. *Invest Ophthalmol Vis Sci*. 2010 Sep;51(9):4788-91. doi: 10.1167/iovs.09-4976. PMID: 20435585. Epub 2010 Apr 30.
18. Piemarocchi S, Varano M, **Parravano M**, Oddone F, Sartore M, Ferrara R, Sera F and Virgili G. Quality of Vision Index (QOVI): A New Method to Appraise Visual Function Changes in Age-related Macular Degeneration. *Eur J Ophthalmol*. 2011 Jan-Feb;21(1):55-66. doi: 10.5301/ejo.2010.1519. PMID: 20640999
19. Tanga L, Centofanti M, Oddone F, **Parravano M**, Parisi V, Ziccardi L, Kroegler B, Perricone R, Manni G. Retinal functional changes measured by frequency-doubling technology in patients treated with hydroxychloroquine. *Graefes Arch Clin Exp Ophthalmol*. 2011 May;249(5):715-21. doi: 10.1007/s00417-010-1612-6. PMID: 21253758. Epub 2011 Jan 21.
20. Oddone F, Centofanti M, Tanga L, Parravano M, Michelessi M, Schiavone M, Villani CM, Fogagnolo P, Manni G. Influence of Disc Size on Optic Nerve Head versus

- Retinal Nerve Fiber Layer Assessment for Diagnosing Glaucoma. *Ophthalmology*. 2011 Jul;118(7):1340-7. doi: 10.1016/j.ophtha.2010.12.017. PMID: 21474186. Epub 2011 Apr 7.
21. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM; Ozurdex GENEVA Study Group, Li J. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. *Ophthalmology*. 2011 Dec;118(12):2453-60. doi: 10.1016/j.ophtha.2011.05.014. PMID: 21764136. Epub 2011 Jul 20.
 22. **Parravano M**, Pilotto E, Musicco I, Varano M, Intorini U, Staurenghi G, Menchini U, Virgili G. Reproducibility of fluorescein and indocyanine green angiographic assessment for RAP diagnosis: a multicenter study. *Eur J Ophthalmol*. 2011 Nov 28:0. doi: 10.5301/ejo.5000087. PMID: 22139618. [Epub ahead of print]
 23. **Parravano M**, Sciamanna M, Giorno P, Boninfante A, Varano M. Bietti crystalline dystrophy: a morpho-functional evaluation. *Doc Ophthalmol*. 2012 Feb;124(1):73-7. doi: 10.1007/s10633-011-9309-7. PMID: 22205354. Epub 2011 Dec 29.
 24. Reibaldi M, **Parravano M**, Varano M, Longo A, Avitabile T, Uva MG, Zagari M, Toro M, Boscia F, Boccassini B, Chiaravalloti A, Mariotti C, Reibaldi A. Foveal Microstructure and Functional Parameters in Lamellar Macular Hole. *Am J Ophthalmol* 2012 Dec;154(6):974-980.e1. doi: 10.1016/j.ajo.2012.06.008. PMID: 22967862. Epub 2012 Sep 8.
 25. Cacciamani A, Oddone F, **Parravano M**, Scarinci F, Di Nicola M, Lofoco G. Intravitreal injection of bevacizumab: changes in intraocular pressure related to ocular axial length. *Jpn J Ophthalmol* 2013 Jan;57(1):63-7. doi: 10.1007/s10384-012-0194-8. PMID: 2309331. Epub 2012 Oct 24.
 26. Virgili G, **Parravano M**, Menchini F, Brunetti M. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. *Cochrane Database Syst Rev*. 2012 Dec 12;12:CD007419.doi:10.1002/14651858.CD007419.pub3. PMID: 23235642
 27. **Parravano M**, Oddone F, Boccassini B, Chiaravalloti A, Scarinci F, Sciamanna M, Boninfante A, Tedeschi M, Varano M. Functional and structural assessment of lamellar macular holes. *Br J Ophthalmol*. 2013 Mar;97(3):291-6. doi: 10.1136/bjophthalmol-2011-301219. PMID: 23258213. Epub 2012 Dec 19.
 28. Lombardo M, Serrao S, Devaney N, **Parravano M**, Lombardo G. Adaptive optics technology for high-resolution retinal imaging. *Sensors (Basel)*. 2012 Dec 27;13(1):334-66.doi: 10.3390/s130100334. PMID: 23271600 [PubMed - in

- process]
29. **Parravano M**, Oddone F, Boccassini B, Centofanti M, Tanga L, Cacciamani A, Borboni P, Varano M. Functional retinal impairment in type 1 diabetic patients without any signs of retinopathy. *Ophthalmic Res.* 2013 Jul 3;50(2):108-112 doi: 10.1159/000350412. PMID: 23838724. Epub 2013 Jul 3.
 30. Lombardo M, **Parravano M**, Serrao S, Ducoli P, Stirpe M, Lombardo G. Analysis of retinal capillaries in patients with type 1 diabetes and non proliferative diabetic retinopathy using adaptive optics imaging. *Retina.* 2013 Sep;33(8):1630-9. doi: 10.1097/IAE.0b013e3182899326. PMID: 23492950
 31. Lombardo M, **Parravano M**, Lombardo G, Varano M, Boccassini B, Stirpe M, Serrao S. Adaptive optics imaging of parafoveal cones in type 1 diabetes. *Retina* 2014;34(3):546-57. doi: 10.1097/IAE.0b013e3182a10850. PMID: 23928676
 32. Varano M, Boninfante A, Ziccardi L, Oddone F, Giorno P, Lioi S, Valli Fiore V, De Geronimo D, Parisi V, **Parravano M**. Modificazioni retiniche morfo-funzionali a lungo termine nella degenerazione maculare di tipo secco in terapia con supplementazione orale a base di Luteina, Zeaxantina, DHA microalgale, Tocotrienoli, Vitamine e minerali.” *Ottica Fisiopatologica* Marzo 2013
 33. Virgili G, **Parravano M**, Menchini F, Brunetti M. Cost-effectiveness of treatments for diabetic macular oedema: should we pay more attention to the appraisal and reporting of economic evaluations? *Br J Ophthalmol.* 2014 Apr;98(4):421-2. doi: 10.1136/bjophthalmol-2013-303352. PMID: 23786886 Epub 2013 Jun 20.
 34. **Parravano M**, Parisi V, Ziccardi L, Chiaravalloti A, Tedeschi M, Cacciamani A, Boccassini B, Boninfante A, Varano M. Single-session photodynamic therapy combined with intravitreal ranibizumab for neovascular age-related macular degeneration: a comprehensive functional retinal assessment. *Doc Ophthalmol.* 2013 Dec;127(3):217-25 doi: 10.1007/s10633-013-9404-z. PMID: 23943132 Epub 2013 Aug 13.
 35. Lazzeri S, Piaggi P, **Parravano M**, et al. Analysis of Functional Dissociations between Best Corrected Visual Acuity and Microperimetric Parameters in Neovascular Age-Related Macular Degeneration Patients Underwent to Three Monthly Ranibizumab Injections. *J Clin Exp Ophthalmol* 2013, 4:4 DOI: 10.4172/2155-9570.1000293
 36. Coscas G, Augustin A, Bandello F, de Smet M, Lanzetta P, Staurenghi G, **Parravano M**, Udaondo P, Moisseiev E, Soubrane G, Yatziv Y, Loewenstein A. Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion. *Eur J Ophthalmol.* 2014 Jan-Feb;24(1):1-9. doi: 10.5301/ejo.5000376. PMID: 24249150 Epub 2013 Oct 14.

37. **Parravano M**, Oddone F, Boccassini B, Giorno P, Chiaravalloti A, Tedeschi M, Scarinci F, Varano M. Exploring the morphological and functional retinal changes after Dexamethasone Intravitreal Implant (Ozurdex®) in macular edema due to retinal vein occlusion. *Ophthalmic Res.* 2014;51(3):153-60. doi: 10.1159/000357275. PMID: 24642474 Epub 2014 Mar 13.
38. Varano M, Iacono P, Giorno P, Chiaravalloti A, **Parravano M**. Photodynamic therapy in subfoveal and juxtafoveal myopic choroidal neovascularization: 10 years retrospective analysis. *Ophthalmologica.* 2014;231(4):204-10 doi: 10.1159/000357504. PMID: 24481122 Epub 2014 Jan 25.
39. **Parravano M**, Ricci F, Oddone F, Missiroli F, De Felici C, Varano M. Long term functional and morphological retinal changes after ranibizumab and photodynamic therapy in myopic choroidal neovascularization. *Retina.* 2014 Oct;34(10):2053-62. doi:10.1097/IAE.0000000000000201. PMID: 24946101
40. **Parravano M**, Oddone F, Giorno P, Cacciamani A, Abbate R, Caminiti G, Peiretti E, Varano M. Influence of macular choroidal thickness on visual function in highly myopic eyes. *Ophthalmic Res.* 2014;52(2):97-101. doi: 10.1159/000362880. PMID: 25195636 Epub 2014 Sep 2.
41. Matteucci A, Gaddini L, Villa M, Varano M, **Parravano M**, Monteleone V, Cavallo F, Leo L, Mallozzi C, Malchiodi-Albedi F, Pricci F. Neuroprotection by rat Müller glia against high glucose-induced neurodegeneration through a mechanism involving ERK1/2 activation. *Exp Eye Res.* 2014 Aug;125:20-9. doi: 10.1016/j.exer.2014.05.011. PMID: 24877742 Epub 2014 May 28.
42. Cacciamani A, Scarinci F, **Parravano M**, Giorno P, Varano M. Choroidal thickness changes with photodynamic therapy for a diffuse choroidal hemangioma in Sturge-Weber syndrome. *Int Ophthalmol* 2014 Oct;34(5):1131-5. doi: 10.1007/s10792-014-9933-9. PMID: 24658736 [Epub ahead of print]
43. Lazzeri S, Figus M, Sartini MS, Scarinci F, Casini G, Guidi G, Cupo G, Cacciamani A, Fasanella V, Agnifili L, Piaggi P, Varano M, Ripandelli G, Nardi M, **Parravano M**. Intravitreal ranibizumab for predominantly haemorrhagic choroidal neovascularization in age related macular degeneration. *Ophthalmologica.* 2015;233(2):74-81. doi: 10.1159/000371393. PMID: 25662794. Epub 2015 Jan 30.
44. Bandello F, Parravano M, Cavallero E, Cascavilla ML, Triolo G, Querques L, Borrelli E, Giorno P, Varano M, Lattanzio R, Querques G. Prospective evaluation of morphological and functional changes after repeated intravitreal dexamethasone implant (Ozurdex®) for retinal vein occlusion. *Ophthalmic Res.* 2015;53(4):207-16. doi: 10.1159/000381187. PMID: 25896233. Epub 2015 Apr 16.

45. Virgili G, **Parravano M**, Menchini F, Evans JR. Anti-vascular endothelial growth factor for diabetic macular oedema. *Cochrane Database Syst Rev*. 2014 Oct 24;10:CD007419. doi: 10.1002/14651858.CD007419.pub4. PMID: 25342124 [Epub ahead of print]
46. **Parravano M**, Giansanti F, Eandi CM, Yap YC, Rizzo S, Virgili G. Vitrectomy for idiopathic macular hole. *Cochrane Database Syst Rev*. 2015 May 12;5:CD009080. doi: 10.1002/14651858.CD009080.pub2. PMID: 25965055.
47. Parodi Battaglia M, Iacono P, Petruzzi G, **Parravano M**, Varano M, Bandello F. Dexamethasone Implant for Macular Edema Secondary to Ischemic Retinal Vein Occlusions. *Retina*. 2015 Jul;35(7):1387-92 doi: 10.1097/IAE.0000000000000492 PMID: 26102438
48. Maurizio B.Parodi, Pierluigi Iacono, Giuseppe Petruzzi, **Mariacristina Parravano**, Monica Varano, Francesco Bandello. Dexamethasone Implant for Macular Edema Secondary to Central Retinal Vein Occlusion in patients aged under 50 years. *Retina*. 2015 Jul;35(7):1381-6. doi: 10.1097/IAE.0000000000000494. PMID: 26102437
49. Stefano Lazzeri, Guido Ripandelli, Maria Sole Sartini, **Mariacristina Parravano**, Monica Varano, Marco Nardi, Teresa Di Desidero, Paola Orlandi, Guido Bocci. Aflibercept administration in neovascular age related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward. *Angiogenesis* 2015 Oct;18(4):397-432. doi: 10.1007/s10456-015-9483-4. PMID: 26346237 Epub 2015 Sep 7.
50. Valentina Sarao, **Mariacristina Parravano**, Daniele Veritti, Luis Arias, Monica Varano, Paolo Lanzetta. Intravitreal Aflibercept for Choroidal Neovascularization Due to Age-Related Macular Degeneration Unresponsive to Ranibizumab Therapy. *Retina*. 2016 Apr;36(4):770-7. doi: 10.1097/IAE.0000000000000751. PMID: 26398691
51. Cacciamani A, **Parravano M**, Scarinci F, Esposito G, Varano M, Micera A. A Simple Spontaneous Vitreal Reflux Collecting Procedure During Intravitreal Injection: Set-Up and Validation Studies. *Curr Eye Res*. 2015 Oct 15:1-6. doi: 10.3109/02713683.2015.1080282 PMID: 26470652 Epub 2015 Oct
52. 15.Ribeiro L, Bandello F, Tejerina AN, Vujosevic S, Varano M, Egan C, Sivaprasad S, Menon G, Massin P, Verbraak FD, Lund-Andersen H, Martinez JP, Jürgens I, Smets E, Coriat C, Wiedemann P, Ágoas V, Querques G, Holz FG, Nunes S, Neves C, Cunha-Vaz J; Evicr Net Study Group. Characterization of Retinal Disease Progression in a 1-Year Longitudinal Study of Eyes With Mild Nonproliferative Retinopathy in Diabetes Type 2. *Invest Ophthalmol Vis Sci*. 2015 Aug;56(9):5698-705. doi: 10.1167/iovs.15-16708. PMID: 26322834

53. Manuele Michelessi, Ersilia Lucenteforte, Francesco Oddone, Miriam Brazzelli, **Mariacristina Parravano**, Sara Franchi, Sueko M Ng, Gianni Virgili. Optic nerve head and fibre layer imaging for diagnosing glaucoma. *Cochrane Database Syst Rev*. Online 30 Nov 2015. doi: 10.1002/14651858.CD008803.pub2. PMID: 26618332
54. Lazzeri S, Orlandi P, Piaggi P, Sartini MS, Casini G, Guidi G, Figus M, Fioravanti A, Di Desidero T, Ripandelli G, **Parravano M**, Varano M, Nardi M, Bocci G. IL-8 and VEGFR-2 polymorphisms modulate long-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration. *Pharmacogenomics*. 2016;17(1):35-9. doi: 10.2217/pgs.15.153. PMID: 26653034 Epub 2015 Dec 14.
55. **Parravano M**, Querques L, Boninfante A, Giorno P, Varano M, Bandello F, Querques G. Reticular pseudodrusen characterization by retromode imaging. *Acta Ophthalmol* 2017 May;95(3):e246-e248. doi: 10.1111/aos.12948. PMID: 26815408. Epub 2016 Jan 27.
56. Oddone F, Lucenteforte E, Michelessi M, Rizzo S, Donati S, **Parravano M**, Virgili G. Macular versus Retinal Nerve Fiber Layer Parameters for Diagnosing Manifest Glaucoma: A Systematic Review of Diagnostic Accuracy Studies. *Ophthalmology* 2016 May;123(5):939-49. doi: 10.1016/j.ophtha.2015.12.041. PMID: 26891880 Epub 2016 Feb 15.
57. Lombardo M, **Parravano M**, Serrao S, Ziccardi L, Giannini D, Lombardo G. Investigation of Adaptive Optics Imaging Biomarkers for Detecting Pathological Changes of the Cone Mosaic in Patients with Type 1 Diabetes Mellitus. *PLoS One*. 2016 Mar 10;11(3):e0151380. doi: 10.1371/journal.pone.0151380. PMID: 26963392. eCollection 2016.
58. Virgili G, **Parravano M**, Schmucker C. Managing Neovascular Age-Related Macular Degeneration: Is More Research Needed to Improve Real-world Practice? *JAMA Ophthalmol*. 2016 Mar 24. doi: 10.1001/jamaophthalmol.2016.0332. PMID: 27010383[Epub ahead of print] No abstract available.
59. Cacciamani A, Lazzeri S, Rossi T, Scarinci F, **Parravano M**, Ripandelli G, Pileri MA, Nardi M, Stirpe M. ADJUSTABLE MACULAR BUCKLING FOR FULL-THICKNESS MACULAR HOLE WITH FOVEOSCHISIS IN HIGHLY MYOPIC EYES: Long-Term Anatomical and Functional Results. *Retina*. 2016 Apr;36(4):709-16. doi: 10.1097/IAE.0000000000000802. PMID: 27018807
60. Ricci F, **Parravano M**, Regine F, Sciamanna M, Tedeschi M, Missiroli F, Varano M. Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy. *Eye (Lond)* 2017 Jan;31(1):163-164. doi: 10.1038/eye.2016.215 PMID: 27716748. Epub 2016 Oct 7.
61. **Parravano M**, Querques L, Scarinci F, Giorno P, De Geronimo D, Gattegna R,

- Varano M, Bandello F, Querques G. Optical coherence tomography angiography in treated type 2 neovascularization undergoing monthly anti-VEGF treatment. *Acta Ophthalmol* 2017 Aug;95(5):e425-e426. doi: 10.1111/aos.13180. PMID: 27496070. Epub 2016 Aug 6.No abstract available.
62. Ricci F, **Parravano M**, Regine F, Sciamanna M, Tedeschi M, Missiroli F, Varano M. Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy. *Eye (Lond)*. 2017 Jan;31(1):163-164. doi: 10.1038/eye.2016.215. PMID: 27716748 Epub 2016 Oct 7. No abstract available.
63. Iacono Pierluigi, Battaglia Parodi Maurizio, Federico Selvi, **Mariacristina Parravano**, Chiaravalloti Adele, Varano Monica, Bandello Francesco. Factors influencing visual acuity in patients receiving anti-VEGF for myopic choroidal neovascularization. *Retina* 2017 Oct;37(10):1931-1941. doi: 10.1097/IAE.0000000000001436. PMID: 28033235
64. Veritti D, Sarao V, **Parravano M**, Arias L, Varano M, Lanzetta P. One-year results of aflibercept in vascularized pigment epithelium detachment due to neovascular AMD: a prospective study. *Eur J Ophthalmol*. 2017 Jan 19;27(1):74-79. doi: 10.5301/ejo.5000880. PMID: 27791249 Epub 2016 Oct 27.
65. Longo A, Casuccio A, Pani L, Avitabile T, Cillino S, Uva MG, Bonfiglio V, Russo A, Parisi G, Cennamo G, Furino C, **Parravano M**, Xoxi E, Reibaldi M. Association of neovascular age-related macular degeneration with month and season of birth in Italy. *Aging (Albany NY)*. 2016 Dec 19;9(1):133-141. doi: 10.18632/aging.101137. PMID: 27997361
66. Scarinci F, Picconi F, Virgili G, Giorno P, Di Renzo A, Varano M, Frontoni S, **Parravano M**. Single retinal layer evaluation in patients with type 1 diabetes with no or early signs of diabetic retinopathy: the first hint of neurovascular crosstalk damage between neurons and capillaries? *Ophthalmologica* 2017;237(4):223-231. doi: 10.1159/000453551 PMID: 28391270 Epub 2017 Apr 8.
67. Joseph M. Simonett, MD, Fabio Scarinci, MD, Fabiana Picconi, MD, Paola Giorno, MD, Daniele De Geronimo, MD, Antonio Di Renzo, PhD, Monica Varano, MD, Simona Frontoni, MD, PhD, **Mariacristina Parravano**, MD Early microvascular retinal changes on Optical Coherence Tomography Angiography in patients with Type 1 Diabetes Mellitus. *Acta Ophthalmol*. 2017 Dec;95(8):e751-e755. doi: 10.1111/aos.13404..PMID: 28211261 Epub 2017 Feb 16
68. Fabiana Picconi, **Mariacristina Parravano**, Dorina Ylli, Patrizio Pasqualetti, Sara Coluzzi, Ilaria Giordani, Ilaria Malandrucchio, Davide Lauro, Fabio Scarinci, Paola Giorno, Monica Varano, Simona Frontoni. Early retinal neurodegeneration in patients with type 1 diabetes mellitus: the role of glycemic variability. *Acta Diabetol*. 2017 May;54(5):489-497. doi: 10.1007/s00592-017-0971-4. PMID: 28238189 Epub 2017

- Feb 25.
69. **Parravano M**, De Geronimo D, Scarinci F, Querques L, Virgili G, Simonett JM, Varano M, Bandello F, Querques G. Relationship between internal reflectivity of diabetic microaneurysms on SD-OCT and detection on OCT Angiography. *Am J Ophthalmol*. 2017 May 5. pii: S0002-9394(17)30190-3. doi: 10.1016/j.ajo.2017.04.021. [Epub ahead of print]
 70. Querques L, **Parravano M**, Sacconi R, Rabiolo A, Bandello F, Querques G. Ischemic index changes in diabetic retinopathy after intravitreal dexamethasone implant using ultra-widefield fluorescein angiography: a pilot study. *Acta Diabetol* 2017 Aug;54(8):769-773. doi: 10.1007/s00592-017-1010-1. PMID: 28577137 Epub 2017 Jun 2.
 71. Varano M, Iacono P, Tedeschi MM, Letizia C, Curione M, Savoriti C, Baiocco E, Zinnamosca L, Marinelli C, Boccassini B, **Parravano M**. Comparisons of microvascular and macrovascular changes in aldosteronism-related hypertension and essential hypertension. *Sci Rep*. 2017 Jun 1;7(1):2666. doi: 10.1038/s41598-017-02622-2. PMID: 28572599
 72. Pilotto E, Guidolin F, **Parravano M**, Viola F, De Geronimo D, Convento E, dell'Arti L, Tabacchi E, Parrozzani R, Cavarzeran F, Midena E. MORPHOFUNCTIONAL EVALUATION IN DOME-SHAPED MACULA: A MICROPERIMETRY AND OPTICAL COHERENCE TOMOGRAPHY STUDY. *Retina* 2018 May;38(5):922-930. doi: 10.1097/IAE.0000000000001621. PMID: 28538084.
 73. Villa M, **Parravano M**, Micheli A, Gaddini L, Matteucci A, Mallozzi C, Facchiano F, Malchiodi-Albedi F, Pricci F. A quick, simple method for detecting circulating fluorescent advanced glycation end-products: Correlation with in vitro and in vivo non-enzymatic glycation. *Metabolism*. 2017 Jun;71:64-69. doi: 10.1016/j.metabol.2017.03.004. PMID: 28521879 Epub 2017 Mar 9.
 74. Rabiolo A, **Parravano M**, Querques L, Cicinelli MV, Carnevali A, Sacconi R, Centoducati T, Vujosevic S, Bandello F, Querques G. Ultra-wide-field fluorescein angiography in diabetic retinopathy: a narrative review. *Clin Ophthalmol*. 2017 Apr 27;11:803-807. doi: 10.2147/OPTH.S133637. PMID: 28490862 eCollection 2017. Review.
 75. Marchese A, **Parravano M**, Rabiolo A, Carnevali A, Corbelli E, Cicinelli MV, Battaglia Parodi M, Querques L, Bandello F, Querques G. Optical coherence tomography analysis of evolution of Bruch's membrane features in angioid streaks. *Eye (Lond)* 2017 Nov;31(11):1600-1605. doi: 10.1038/eye.2017.112. Epub 2017 Jun 16.
 76. Virgili G, **Parravano M**, Evans JR, Gordon I, Lucenteforte E. Anti-vascular

- endothelial growth factor for diabetic macular oedema: a network meta-analysis. *Cochrane Database Syst Rev* 2018 Oct 16;10(10):CD007419. doi: 10.1002/14651858.CD007419.pub6.. Review. PubMed PMID: 30325017
77. Eandi CM, Ciardella A, **Parravano M**, Missiroli F, Alovise C, Veronese C, Morara MC, Grossi M, Virgili G, Ricci F. Indocyanine Green Angiography and Optical Coherence Tomography Angiography of Choroidal Neovascularization in Age-Related Macular Degeneration. *Invest Ophthalmol Vis Sci*. 2017 Jul 1;58(9):3690-3696. doi:10.1167/iovs.17-21941. PubMed PMID: 28738134.
78. Scarinci F, Picconi F, Giorno P, Boccassini B, De Geronimo D, Varano M, Frontoni S, **Parravano M**. Deep capillary plexus impairment in patients Type 1 Diabetes Mellitus with no signs of diabetic retinopathy revealed using optical coherence tomography angiography. *Acta Ophthalmol* 2018 Mar;96(2):e264-e265. doi: 10.1111/aos.13510. PMID: 28887911 Epub 2017 Sep 9.
79. **Parravano M**, Scarinci F, Gilardi M, Querques L, Varano M, Oddone F, Bandello F, Querques G. Patchy Chorioretinal Atrophy Changes at the Posterior Pole After Ranibizumab for Myopic Choroidal Neovascularization. *Invest Ophthalmol Vis Sci*. 2017 Dec 1;58(14):6358-6364. doi: 10.1167/iovs.17-22633. PMID: 29260192 PubMed
80. Iacono P, Tedeschi M, Boccassini B, Chiaravalloti A, Varano M, **Parravano M**. CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Early and Late Morphological and Functional Changes After Verteporfin Photodynamic Therapy. *Retina*. 2018 Jan 16. doi: 10.1097/IAE.0000000000002040. PMID: 29346241 [Epub ahead of print]
81. Mallozzi C, **Parravano M**, Gaddini L, Villa M, Pricci F, Malchiodi-Albedi F, Matteucci A. Curcumin Modulates the NMDA Receptor Subunit Composition Through a Mechanism Involving CaMKII and Ser/Thr Protein Phosphatases. *Cell Mol Neurobiol*. 2018 May 30. doi: 10.1007/s10571-018-0595-4 PMID: 29846839. Epub 2018 May 30.
82. Giovannini A, **Parravano M**, Ricci F, Bandello F. Management of diabetic macular edema with intravitreal dexamethasone implants: Expert recommendations using a Delphi-based approach. *Eur J Ophthalmol* 2019 Jan;29(1):82-91. doi: 10.1177/1120672118781236.. PMID:29882421 Epub 2018 Jun 8.
83. Virgili G, Evans J, **Parravano M**. Prioritizing Questions and Outcomes for Guidelines on Age-Related Macular Degeneration: Moving Beyond the Clinical Encounter. *JAMA Ophthalmol*. 2018 Aug 16. doi: 10.1001/jamaophthalmol.2018.3455. PMID: 30128568 [Epub ahead of print].

84. Ziccardi L, Parisi V, Picconi F, Di Renzo A, Lombardo M, Frontoni S, **Parravano M**. Early and localized retinal dysfunction in patients with type 1 diabetes mellitus studied by multifocal electroretinogram. *Acta Diabetol*. 2018 Aug 28. doi: 10.1007/s00592-018-1209-9. PMID: 30159747 Epub 2018 Aug 28.
85. **Parravano M**, De Geronimo D, Scarinci F, Virgili G, Querques L, Varano M, Bandello F, Querques G. Progression of diabetic microaneurysms according to the internal reflectivity on structural OCT and visibility on OCT angiography. *Am J Ophthalmol*. 2018 Oct 8. pii: S0002-9394(18)30573-7. doi: 10.1016/j.ajo.2018.09.031. PMID: 30308201 Epub 2018 Oct 9.
86. Bellanca RF, Scarinci F, **Parravano M**. Multimodal imaging in a young male with osteogenesis imperfecta complicated with choroidal neovascularization. *Eur J Ophthalmol*. 2018 Nov 8;1120672118811247. doi: 10.1177/1120672118811247 PMID: 30409043. Epub 2018 Nov 8.
87. Pepe J, Cipriani C, Tedeschi M, Curione M, **Parravano M**, Varano M, Biamonte F, Colangelo L, Minisola S. Retinal micro-vascular and aortic macro-vascular changes in postmenopausal women with primary hyperparathyroidism. *Sci Rep*. 2018 Nov 8;8(1):16521. doi: 10.1038/s41598-018-35017-y. PubMed PMID: 30410012; PubMed Central PMCID: PMC6224616.
88. Picconi F, Mataluni G, Ziccardi L, **Parravano M**, Di Renzo A, Ylli D, Pasqualetti P, Studer V, Chioma L, Marfia GA, Frontoni S. Association between Early Neuroretinal Dysfunction and Peripheral Motor Unit Loss in Patients with Type 1 Diabetes Mellitus. *J Diabetes Res*. 2018 Oct 4;2018:9763507. Doi 10.1155/2018/9763507. eCollection 2018. PubMed PMID: 30402503; PubMed Central PMCID: PMC6193343.
89. Cacciamani A, Esposito G, Scarinci F, **Parravano M**, Dinice L, Di Nicola M, Micera A. Inflammatory mediators in the vitreal reflux of patients with diabetic macular edema. *Graefes Arch Clin Exp Ophthalmol*. 2018 Oct 30. doi: 10.1007/s00417-018-4169-4. PMID: 30377797. Epub 2018 Oct 30.
90. Scarinci F, Ghiciuc CM, Patacchioli FR, Palmery M, **Parravano M**. Investigating the Hypothesis of Stress System Dysregulation as a Risk Factor for Central Serous Chorioretinopathy: A Literature Mini-Review. *Curr Eye Res*. 2019 Jan 9:1-7. doi: 10.1080/02713683.2019.1565891. PMID: 30624085. Epub 2019 Jan 28.
91. Iacono P, Toto L, Eliana C, Varano M, **Parravano MC**. Pharmacotherapy of central serous chorioretinopathy: review of the current treatments. *Curr Pharm Des*. 2019 Jan 23. doi: 10.2174/1381612825666190123165914. [Epub ahead of print] PMID: 30674250.

92. Costanzo E, **Parravano M**, Gilardi M, Cavalleri M, Sacconi R, Aragona E, Varano M, Bandello F, Querques G. Microvascular Retinal and Choroidal Changes in Retinal Vein Occlusion Analyzed by Two Different Optical Coherence Tomography Angiography Devices. *Ophthalmologica*. 2019 Feb 5:1-8. doi: 10.1159/000496195. PMID: 30721901. Epub 2019 Feb 5.
93. Sciarretta F, Fulci C, Palumbo C, Aquilano K, Pastore A, Iorio E, Lettieri-Barbato D, Cicconi R, Minutolo A, **Parravano M**, Gilardi M, Varano M, Caccuri AM. Glutathione transferase P silencing promotes neuronal differentiation of retinal R28 cells. *J Cell Physiol*. 2019 Feb 11. doi: 10.1002/jcp.28246. PMID: 30741416. Epub 2019 Feb 11.
94. Panozzo G, Staurenghi G, Dalla Mura G, Giannarelli D, Alessio G, Alongi S, Appolloni R, Baldascino A, Boscia F, Caporossi A, Cereda M, D'Ugo E, Fallico M, Avitabile T, Galan A, La Spina C, Lo Giudice G, Mastropasqua L, Palmisano C, Panico C, **Parravano MC**, Penna R, Pintore P, Vaiano A, Reibaldi M, Rizzo S, Rossi T, Varano M, Virgili G. Prevalence of diabetes and diabetic macular edema in patients undergoing senile cataract surgery in Italy: The DIabetes and CATaract study. *Eur J Ophthalmol*. 2019 Mar 11:1120672119830578. doi: 10.1177/1120672119830578. PMID: 30854895. Epub 2019 Mar 11.
95. Corbelli E, **Parravano M**, Sacconi R, Sarraf D, Yu SY, Kim K, Capuano V, Miere A, Souied E, Varano M, Boninfante A, Chae B, Carnevali A, Querques L, Bandello F, Querques G. Prevalence and Phenotypes of Age-Related Macular Degeneration in Eyes With High Myopia. *Invest Ophthalmol Vis Sci*. 2019 Apr 1;60(5):1394-1402. doi:10.1167/iovs.18-25534. PubMed PMID: 30938774.
96. **Parravano M**, Borrelli E, Sacconi R, Costanzo E, Marchese A, Manca D, Varano M, Bandello F, Querques G. A Comparison Among Different Automatically Segmented Slabs to Assess Neovascular AMD using Swept Source OCT Angiography. *Transl Vis Sci Technol*. 2019 Mar 27;8(2):8. doi: 10.1167/tvst.8.2.8. eCollection 2019 Mar. PubMed PMID: 30941265; PubMed Central PMCID: PMC6438244.
97. Virgili G, **Parravano M**, Viola F, Varano M. Vision-related quality of life in patients treated for myopic choroidal neovascularization: A post hoc analysis of the OLIMPIC study. *Eur J Ophthalmol*. 2020 Sep;30(5):10-69-1075. doi: 10.1177/1120672119853745. Epub 2019 Jun 6. PMID: 31169023.
98. Picconi F, **Parravano M**, Sciarretta F, Fulci C, Nali M, Frontoni S, Varano M, Maria Caccuri A. Activation of retinal Müller cells in response to glucose variability. *Endocrine*. 2019 Sep;65(3):542-549. doi: 10.1007/s12020-019-02017-5. PMID: 31327157

99. Schiano Lomoriello D, Abicca I, **Parravano M**, Giannini D, Russo B, Frontoni S, Picconi F. Early Alterations of Corneal Subbasal Plexus in Uncomplicated Type 1 Diabetes Patients. *J Ophthalmol*. 2019 Jul 2;2019:9818217. doi: 10.1155/2019/9818217. eCollection 2019. PubMed PMID: 31341662; PubMed Central PMCID: PMC6636466.
100. Cavalleri M, Cicinelli MV, **Parravano M**, Varano M, De Geronimo D, Sacconi R, Bandello F, Querques G. Prognostic role of optical coherence tomography after switch to dexamethasone in diabetic macular edema. *Acta Diabetol*. 2020 Feb;57(2):163-171. Doi10.1007/s00592-019-01389-4. Epub 2019 Aug 2. PMID 31375988
101. Borrelli E, Zuccaro B, Zucchiatti I, **Parravano M**, Querques L, Costanzo E, Sacconi R, Prascina F, Scarinci F, Bandello F, Querques G. Optical Coherence Tomography Parameters as Predictors of Treatment Response to Eplerenone in Central Serous Chorioretinopathy. *J Clin Med*. 2019 Aug 22;8(9):1271. doi: 10.3390/jcm8091271. PubMed PMID: 31443376. PMCID: PMC6781176
102. **Parravano M**, Tedeschi M, Manca D, Costanzo E, Di Renzo A, Giorno P, Barbano L, Ziccardi L, Varano M, Parisi V. Correction to: Effects of Macuprev(®) Supplementation in Age-Related Macular Degeneration: A Double-Blind Randomized Morpho-Functional Study Along 6 Months of Follow-Up. *Adv Ther*. 2019 Nov;36(11):3288. doi: 10.1007/s12325-019-01094-2. PubMed PMID: 31538305; PubMed Central PMCID: PMC6822796.
103. Accorinti M, Gilardi M, De Geronimo D, Iannetti L, Giannini D, **Parravano M**. Optical Coherence Tomography Angiography Findings in Active and Inactive Ocular Behçet Disease. *Ocul Immunol Inflamm*. 2020 May 18;28(4):589-600. doi: 10.1080/09273948.2019.1612452. Epub 2019 Sep 27. PMID: 31560572.
104. Iacono P, Giorno P, Varano M, **Parravano M**. Structural and optical coherence tomography angiography in myopic choroidal neovascularization: Agreement with conventional fluorescein angiography. *Eur J Ophthalmol*. 2021 Jan;31(1):149-157. doi: 10.1177/1120672119882333. Epub 2019 Oct 17. PMID: 31619075
105. Scarinci F, Varano M, **Parravano M**. Retinal Sensitivity Loss Correlates with Deep Capillary Plexus Impairment in Diabetic Macular Ischemia. *J Ophthalmol*. 2019 Oct 13;2019:7589841. doi: 10.1155/2019/7589841. eCollection 2019. PubMed PMID: 31737359; PubMed Central PMCID: PMC6815547.
106. Borrelli E, Costanzo E, **Parravano M**, Viggiano P, Varano M, Giorno P, Marchese A, Sacconi R, Mastropasqua L, Bandello F, Querques G. Impact of Bleaching on

- Photoreceptors in Different Intermediate AMD Phenotypes. *Transl Vis Sci Technol.* 2019 Nov 12;8(6):5. doi: 10.1167/tvst.8.6.5. eCollection 2019 Nov. PMID: 31737429
107. Ziccardi L, Cordeddu V, Gaddini L, Matteucci A, **Parravano M**, Malchiodi-Albedi F, Varano M. Gene Therapy in Retinal Dystrophies. *Int J Mol Sci.* 2019 Nov 14;20(22):5722. doi: 10.3390/ijms20225722. PMID: 31739639
108. Borrelli E, **Parravano M**, Querques L, Sacconi R, Giorno P, De Geronimo D, Bandello F, Querques G. One-year follow-up of ischemic index changes after intravitreal dexamethasone implant for diabetic macular edema: an ultra-widefield fluorescein angiography study. *Acta Diabetol.* 2020 May;57(5):543-548. doi: 10.1007/s00592-019-01435-1. Epub 2019 Nov 21. PMID: 31749052
109. De Geronimo D, Giorno P, Scarinci F, Boninfante A, Varano M, **Parravano M**. Treatment of Diabetic Macular Edema with Multiple Dexamethasone Intravitreal Implants: Evidence from Real-Life Experience. *Ophthalmologica.* 2020;243(6):413-419. doi: 10.1159/000504890. Epub 2019 Nov 19. PMID: 31760387.
110. Iacono P, Battaglia Parodi M, **Parravano M**, Varano M. Large choroidal excavation in retinitis pigmentosa: A case report. *Eur J Ophthalmol.* 2020 Sep;30(5):NP66-NP68. doi: 10.1177/1120672119892438. Epub 2019 Dec 4. PMID: 31801355
111. Iacono P, Battaglia Parodi M, Saviano S, **Parravano M**, Varano M. Large choroidal excavation in pachychoroid disease: A case report. *Eur J Ophthalmol.* 2021 Mar;31(2):NP15-NP17. doi: 10.1177/1120672119892428. Epub 2019 Dec 4. PMID: 31801362
112. Giorno P, Iacono P, Scarinci F, Di Renzo A, Varano M, **Parravano M**. Microvasculature Changes of Myopic Choroidal Neovascularization and the Predictive Value of Feeder Vessel Disappearance after Ranibizumab Treatment Revealed Using Optical Coherence Tomography Angiography. *Ophthalmologica.* 2020;243(4):263-270. doi: 10.1159/000504755. Epub 2019 Dec 13. PMID: 31838464.
113. Scarinci F, Patacchioli FR, Palmery M, Pasquali V, Costanzo E, Ghiciuc CM, **Parravano M**. Diurnal trajectories of salivary cortisol and α -amylase and psychological profiles in patients with central serous chorioretinopathy. *Chronobiol Int.* 2020 Apr;37(4):510-519. doi: 10.1080/07420528.2019.1702553. Epub 2019 Dec 16. PMID: 31842621
114. Corbelli E, Borrelli E, **Parravano M**, Sacconi R, Gilardi M, Costanzo E, Cavalleri M, Querques L, Bandello F, Querques G. Multimodal imaging characterization of peripheral drusen. *Graefes Arch Clin Exp Ophthalmol.* 2020 Mar;258(3):543-549. doi: 10.1007/s00417-019-04586-7. Epub 2020 Jan 3. PMID: 31900644

115. Battista M, Borrelli E, **Parravano M**, Gelormini F, Tedeschi M, De Geronimo D, Sacconi R, Querques L, Bandello F, Querques G. OCTA characterisation of microvascular retinal alterations in patients with central serous chorioretinopathy. *Br J Ophthalmol*. 2020 Oct;104(10):1453-1457. doi: 10.1136/bjophthalmol-2019-315482. Epub 2020 Jan 16. PMID: 31949095
116. **Parravano M**, Costanzo E, Borrelli E, Sacconi R, Virgili G, Sadda SR, Scarinci F, Varano M, Bandello F, Querques G. Appearance of cysts and capillary non perfusion areas in diabetic macular edema using two different OCTA devices. *Sci Rep*. 2020 Jan 21;10(1):800. doi: 10.1038/s41598-020-57680-w. PMID: 31964977
117. **Parravano M**, Costanzo E, Querques G. Profile of non-responder and lateresponder patients treated for diabetic macular edema: systemic and ocular factors. *Acta Diabetol*. 2020 Aug;57(8):911-921. doi: 10.1007/s00592-020-01496-7. Epub 2020 Feb 29. PMID: 32114642 Review
118. Eandi CM, De Geronimo D, Giannini D, Polito MS, Tosi GM, Neri G, Le Mer Y, Varano M, **Parravano M**. Baseline SD-OCT characteristics of diabetic macular oedema patterns can predict morphological features and timing of recurrence in patients treated with dexamethasone intravitreal implants. *Acta Diabetol*. 2020 Jul;57(7):867-874. doi: 10.1007/s00592-020-01504-w. Epub 2020 Feb 29. PMID: 32114643 .
119. **Parravano M**, Scarinci F, Parisi V, Giorno P, Giannini D, Oddone F, Varano M. Citicoline and Vitamin B(12) Eye Drops in Type 1 Diabetes: Results of a 3-year Pilot Study Evaluating Morpho-Functional Retinal Changes. *Adv Ther*. 2020 Apr;37(4):1646-1663. doi: 10.1007/s12325-020-01284-3. Epub 2020 Mar 16. PubMed PMID: 32180131. ok
120. Virgili G, **Parravano M**, Gatta G, Capocaccia R, Mazzini C, Mallone S, Botta L; RARECAREnet Working Group. Incidence and Survival of Patients With Conjunctival Melanoma in Europe. *JAMA Ophthalmol*. 2020 Jun 1;138(6):601-608. doi: 10.1001/jamaophthalmol.2020.0531. PMID: 32215588
121. Ziccardi L, Landi D, De Geronimo D, Barbano L, Giorno P, Marfia GA, Albanese M, Parisi V, **Parravano M**. Choriocapillaris Integrity in Relapsed Central Serous Chorioretinopathy in a Patient Treated With Fingolimod for Multiple Sclerosis: New Insights From Optical Coherence Tomography Angiography. *J Neuroophthalmol*. 2021 Mar 1;41(1):e51-e53. doi: 10.1097/WNO.0000000000000937. PMID: 32235227
122. Toto L, Evangelista F, Viggiano P, Erroi E, D'Onofrio G, Libertini D, Porreca A, D'Aloisio R, Parravano M, Di Antonio L, Di Nicola M, Mastropasqua R. Corrigendum to "Changes in Ocular Blood Flow after Ranibizumab Intravitreal Injection for Diabetic Macular Edema Measured Using Laser Speckle Flowgraphy".

- Biomed Res Int. 2020 Jul 1;2020:6219089. doi: 10.1155/2020/6219089. eCollection 2020. PMID: 32695816
123. Parisi V, Ziccardi L, Costanzo E, Tedeschi M, Barbano L, Manca D, Di Renzo A, Giorno P, Varano M, Parravano M. Macular Functional and Morphological Changes in Intermediate Age-Related Maculopathy. *Invest Ophthalmol Vis Sci*. 2020 May 11;61(5):11. doi: 10.1167/iovs.61.5.11. PMID: 32396630
124. Fallico M, Avitabile T, Castellino N, Longo A, Russo A, Bonfiglio V, Parisi F, Furino C, Panozzo G, Scordia V, Carnevali A, Bandello F, Parodi MB, Cennamo G, Cillino S, Vadalà M, Sunseri Trapani V, Cagini C, Fiore T, Lupidi M, Parravano M, Varano M, Giorno P, Boscia F, Giancipoli E, Eandi C, Le Mer Y, Reibaldi M. Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema: the dexcat study. *Acta Ophthalmol*. 2021 Feb;99(1):e74-e80. doi: 10.1111/aos.14516. Epub 2020 Jun 26. PMID: 32588978
125. Scarinci F, Patacchioli FR, Ghiciuc CM, Pasquali V, Bercea RM, Cozma S, Parravano M. Psychological Profile and Distinct Salivary Cortisol Awake Response (CAR) in Two Different Study Populations with Obstructive Sleep Apnea (OSA) and Central Serous Chorioretinopathy (CSC). *J Clin Med*. 2020 Aug 3;9(8):2490. doi: 10.3390/jcm9082490. PMID: 32756367
126. Toto L, D'Aloisio R, Chiarelli AM, Di Antonio L, Evangelista F, D'Onofrio G, Merla A, Parravano M, Di Marzio G, Mastropasqua R. A Custom-Made Semiautomatic Analysis of Retinal Nonperfusion Areas After Dexamethasone for Diabetic Macular Edema. *Transl Vis Sci Technol*. 2020 Jun 11;9(7):13. doi: 10.1167/tvst.9.7.13. eCollection 2020 Jun. PMID: 32832220
127. Mastropasqua R, Evangelista F, Amodei F, D'Aloisio R, Pinto F, Doronzo E, Viggiano P, Porreca A, Di Nicola M, Parravano M, Toto L. Optical Coherence Tomography Angiography in Macular Neovascularization: A Comparison Between Different OCTA Devices. *Transl Vis Sci Technol*. 2020 Oct 7;9(11):6. doi: 10.1167/tvst.9.11.6. eCollection 2020 Oct. PMID: 33101783
128. Scarinci F, Picconi F, Virgili G, Varano M, Giorno P, Frontoni S, Parravano M. Microvascular impairment as a biomarker of diabetic retinopathy progression in the long-term follow up in type 1 diabetes. *Sci Rep*. 2020 Oct 26;10(1):18266. doi: 10.1038/s41598-020-75416-8. PMID: 33106539
129. Iacono P, Da Pozzo S, Varano M, Parravano M. Photodynamic Therapy with Verteporfin for Chronic Central Serous Chorioretinopathy: A Review of Data and Efficacy. *Pharmaceuticals (Basel)*. 2020 Oct 29;13(11):E349. doi: 10.3390/ph13110349. PMID: 33137968

130. Borrelli E, Parravano M, Sacconi R, Costanzo E, Querques L, Vella G, Bandello F, Querques G. Guidelines on Optical Coherence Tomography Angiography Imaging: 2020 Focused Update. *Ophthalmol Ther*. 2020 Dec;9(4):697-707. doi: 10.1007/s40123-020-00286-2. Epub 2020 Aug 1. PMID: 32740741 Review.
131. Lupidi M, Gujar R, Cerquaglia A, Chhablani J, Fruttini D, Muzi A, Corbucci R, Fiore T, Coscas F, Coscas G, Parravano M, Cagini C. OCT-Angiography as a reliable prognostic tool in laser-treated proliferative diabetic retinopathy: The RENOCTA Study. *Eur J Ophthalmol*. 2021 Sep;31(5):2511-2519. doi: 10.1177/1120672120963451. Epub 2020 Nov 2. PMID: 33135494
132. Scarinci F, Varano M, Parravano M. Resilience of the Photoreceptors in Posterior Multifocal Placoid Pigment Epitheliopathy Observed by Microperimetry over Time. *Ocul Immunol Inflamm*. 2022 Feb 17;30(2):379-385. doi: 10.1080/09273948.2020.1817502. Epub 2020 Nov 2. PMID: 33136457
133. Borrelli E, Parravano M, Costanzo E, Sacconi R, Querques L, Pennisi F, De Geronimo D, Bandello F, Querques G. USING THREE-DIMENSIONAL OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY METRICS IMPROVES REPEATABILITY ON QUANTIFICATION OF ISCHEMIA IN EYES WITH DIABETIC MACULAR EDEMA. *Retina*. 2021 Aug 1;41(8):1660-1667. doi: 10.1097/IAE.0000000000003077. PMID: 33332812
134. Querques G, Sacconi R, Capuano V, Carnevali A, Colantuono D, Battista M, Borrelli E, Miere A, Parravano M, Costanzo E, Querques L, Souied EH, Bandello F. Treatment-naïve quiescent macular neovascularization secondary to AMD: The 2019 Young Investigator Lecture of Macula Society. *Eur J Ophthalmol*. 2021 Nov;31(6):3164-3176. doi: 10.1177/1120672120986370. Epub 2021 Jan 14. PMID: 33445977.
135. Borrelli E, Sacconi R, **Parravano M**, Costanzo E, Querques L, Battista M, Grosso D, Giorno P, Bandello F, Querques G. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY ASSESSMENT OF THE DIABETIC MACULA: A Comparison Study Among Different Algorithms. *Retina*. 2021 Sep 1;41(9):1799-1808. doi: 10.1097/IAE.0000000000003145. PMID: 33587426
136. Scarinci F, Picconi F, Virgili G, Varano M, Giorno P, Frontoni S, **Parravano M**. Author Correction: Microvascular impairment as a biomarker of diabetic retinopathy progression in the long-term follow up in type 1 diabetes. *Sci Rep*. 2021 Mar 2;11(1):5399. doi: 10.1038/s41598-021-84931-1. PMID: 33654167
137. Oddone F, Rossetti L, **Parravano M**, Sbardella D, Coletta M, Ziccardi L, Roberti G, Carnevale C, Romano D, Manni G, Parisi V. Citicoline in Ophthalmological

- Neurodegenerative Disease: A Comprehensive Review. Pharmaceuticals (Basel). 2021 Mar 20;14(3):281. doi: 10.3390/ph14030281.PMID: 33804675 Review.
138. Kodjikian L, **Parravano M**, Clemens A, Dolz-Marco R, Holz FG, Munk MR, Nicolò M, Ricci F, Silva R, Talks SJ, Verma RK, Zarranz-Ventura J, Zweifel SA. Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendations. *Eye (Lond)*. 2021 Aug;35(8):2119-2135. doi: 10.1038/s41433-021-01487-0. Epub 2021 Apr 1. PMID: 33795837
139. Sacconi R, Brambati M, Miere A, Costanzo E, Capuano V, Borrelli E, Battista M, **Parravano M**, Souied EH, Bandello F, Querques G. Characterisation of macular neovascularisation in geographic atrophy. *Br J Ophthalmol*. 2022 Sep;106(9):1282-1287. doi: 10.1136/bjophthalmol-2021-318820. Epub 2021 Apr 9. PMID: 33836986
140. **Parravano M**, Ziccardi L, Borrelli E, Costanzo E, Frontoni S, Picconi F, Parisi V, Sacconi R, Di Renzo A, Varano M, Querques G. Outer retina dysfunction and choriocapillaris impairment in type 1 diabetes. *Sci Rep*. 2021 Jul 26;11(1):15183. doi: 10.1038/s41598-021-94580-z. PMID: 34312425
141. Vujosevic S, Cunha-Vaz J, Figueira J, Löwenstein A, Midená E, **Parravano M**, Scanlon PH, Simó R, Hernández C, Madeira MH, Marques IP, C-V Martinho A, Santos AR, Simó-Servat O, Salongcay RP, Zur D, Peto T. Standardisation of Optical Coherence Tomography Angiography Imaging Biomarkers in Diabetic Retinal Disease. *Ophthalmic Res*. 2021 Jul 30. doi: 10.1159/000518620. PMID: 34348330
142. Costanzo E, **Parravano M**, Giannini D, Borrelli E, Sacconi R, Querques G. Imaging Biomarkers of 1-Year Activity in Type 1 Macular Neovascularization. *Transl Vis Sci Technol*. 2021 May 3;10(6):18. doi: 10.1167/tvst.10.6.18. PMID: 34111264
143. **Parravano M**, Petri D, Maurutto E, Lucenteforte E, Menchini F, Lanzetta P, Varano M, van Nispen RMA, Virgili G. [Association Between Visual Impairment and Depression in Patients Attending Eye Clinics: A Meta-analysis](#). *JAMA Ophthalmol*. 2021 Jul 1;139(7):753-761. doi: 10.1001/jamaophthalmol.2021.1557. PMID: 34042966
144. Parisi V, Ziccardi L, Barbano L, Giorno P, Varano M, **Parravano M**. Citicoline and Vitamin B₁₂ Eye Drops in Type 1 Diabetes: Results of a 36-Month Pilot Study Evaluating Macular Electrophysiological Changes. *Adv Ther*. 2021 Jul;38(7):3924-3936. doi: 10.1007/s12325-021-01771-1. Epub 2021 Jun 5. PMID: 34091874

145. Borrelli E, Grosso D, **Parravano M**, Costanzo E, Brambati M, Viganò C, Sacconi R, Querques L, Pina A, De Geronimo D, Bandello F, Querques G. Volume rendered 3D OCTA assessment of macular ischemia in patients with type 1 diabetes and without diabetic retinopathy. *Sci Rep*. 2021 Oct 5;11(1):19793. doi: 10.1038/s41598-021-99297-7. PMID: 34611239
146. **Parravano M**, Costanzo E, Scondotto G, Trifirò G, Virgili G. Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular Degeneration: An Update. *BioDrugs*. 2021 Nov;35(6):673-692. doi: 10.1007/s40259-021-00499-2. Epub 2021 Oct 16. PMID: 34655434 Review.
147. **Parravano M**, Fragiotta S, Costanzo E, Giannini D, De Geronimo D, Viggiano P, Riccardo S, Querques G. Differences in cysts characteristics and related influence on the anatomical response after dexamethasone implant in diabetic macular oedema. *Eye (Lond)*. 2022 Jun;36(6):1329-1331. doi: 10.1038/s41433-021-01857-8. Epub 2021 Nov 24. PMID: 34815531
148. Scarinci F, Patacchioli FR, Costanzo E, **Parravano M**. Relationship of Choroidal Vasculature and Choriocapillaris Flow With Alterations of Salivary α -Amylase Patterns in Central Serous Chorioretinopathy. *Invest Ophthalmol Vis Sci*. 2021 Dec 1;62(15):19. doi: 10.1167/iovs.62.15.19. PMID: 34932061
149. Iacono P, Saviano S, **Parravano M**, Varano M, Battaglia Parodi M. Eye-selfie to resolve the enigmatic diagnosis of transient "eye spot". *Eur J Ophthalmol*. 2022 Jan;32(1):NP59-NP61. doi: 10.1177/1120672120950923. Epub 2020 Aug 17. PMID: 32799552
150. Corbelli E, Sacconi R, Battista M, Bacherini D, Miere A, Borrelli E, Costanzo E, Vella G, **Parravano M**, Ziccardi L, Sodi A, Rizzo S, Souied EH, Bandello F, Querques G. Choroidal vascularity index in eyes with central macular atrophy secondary to age-related macular degeneration and Stargardt disease. *Graefes Arch Clin Exp Ophthalmol*. 2022 May;260(5):1525-1534. doi: 10.1007/s00417-021-05337-3. Epub 2022 Jan 20. PMID: 35048199
151. **Parravano M**, Allegrini D, Carnevali A, Costanzo E, Giannaccare G, Giorno P, Scorcìa V, Spedicato GA, Varano M, Romano MR. Effectiveness of a Hydrophilic Curcumin-Based Formulation in Coadjuvating the Therapeutic Effect of Intravitreal Dexamethasone in Subjects With Diabetic Macular Edema. *Front Pharmacol*. 2022 Jan 4;12:726104. doi: 10.3389/fphar.2021.726104. eCollection 2021. PMID: 35058773
152. Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Efficacy,

- durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. *Lancet*. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. PMID: 35085502 Clinical Trial.
153. Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. *Lancet*. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. PMID: 35085503 Clinical Trial.
154. Udaondo P, **Parravano M**, Vujosevic S, Zur D, Chakravarthy U. Update on Current and Future Management for Diabetic Maculopathy. *Ophthalmol Ther*. 2022 Apr;11(2):489-502. doi: 10.1007/s40123-022-00460-8. Epub 2022 Jan 31. PMID: 35098441
155. Battista M, Sacconi R, Borrelli E, Crepaldi A, Fantaguzzi F, Costanzo E, De Geronimo D, **Parravano M**, Bandello F, Querques G. Discerning Between Macular Hemorrhages Due to Macular Neovascularization or Due to Spontaneous Bruch's Membrane Rupture in High Myopia: A Comparative Analysis Between OCTA and Fluorescein Angiography. *Ophthalmol Ther*. 2022 Apr;11(2):821-831. doi: 10.1007/s40123-022-00484-0. Epub 2022 Feb 20. PMID: 35184253
156. Cavalleri M, Sacconi R, **Parravano M**, Costanzo E, Pezzella M, Bandello F, Querques G. Optical Coherence Tomography Angiography In Central Retinal Vein Occlusion: Macular Changes And Their Correlation With Peripheral Nonperfusion At Ultra-Widefield Fluorescein Angiography. *Ophthalmologica*. 2022;245(3):275-284. doi: 10.1159/000522503. Epub 2022 Feb 10. PMID: 35144261
157. Fragiotta S, Costanzo E, Viggiano P, De Geronimo D, Scuderi G, Varano M, **Parravano M**. Functional Correlates of Outer Retina Remodeling in Intermediate Age-Related Macular Degeneration Using Microperimetry. *Invest Ophthalmol Vis Sci*. 2022 Mar 2;63(3):16. doi: 10.1167/iovs.63.3.16. PMID: 35289843
158. Virgili G, **Parravano M**, Petri D, Maurutto E, Menchini F, Lanzetta P, Varano M, Mariotti SP, Cherubini A, Lucenteforte E. The Association between Vision Impairment and Depression: A Systematic Review of Population-Based Studies. *J Clin Med*. 2022 Apr 25;11(9):2412. doi: 10.3390/jcm11092412. PMID: 35566537

159. Tundo GR, Sbardella D, Oddone F, Grasso G, Marini S, Atzori MG, Santoro AM, Milardi D, Bellia F, Macari G, Graziani G, Polticelli F, Cascio P, **Parravano M**, Coletta M. Insulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug. *Biomolecules*. 2022 Feb 16;12(2):315. doi: 10.3390/biom12020315. PMID: 35204815
160. Abicca I, Giannini D, Gilardi M, Roszkowska AM, **Parravano M**, Picconi F, Frontoni S, Schiano-Lomoriello D. A Novel Algorithm for the Evaluation of Corneal Nerve Beadings by *in vivo* Confocal Microscopy in Patients With Type 1 Diabetes Mellitus. *Front Med (Lausanne)*. 2022 May 12;9:897259. doi: 10.3389/fmed.2022.897259. eCollection 2022. PMID: 35646958
161. **Parravano M**, Eandi CM, Figus M, Lupidi M, Menchini F, Nicolo' M, Parisi V, Toto L, Viola F, Vujosevic S, Querques G. Effects of circadian rhythm disruption on retinal physiopathology: Considerations from a consensus of experts. *Eur J Ophthalmol*. 2022 Sep;32(5):2489-2493. doi: 10.1177/11206721221106149. Epub 2022 Jun 3. PMID: 35656746
162. Mecchia A, Palumbo C, De Luca A, Sbardella D, Boccaccini A, Rossi L, **Parravano M**, Varano M, Caccuri AM. High glucose induces an early and transient cytoprotective autophagy in retinal Müller cells. *Endocrine*. 2022 Aug;77(2):221-230. doi: 10.1007/s12020-022-03079-8. Epub 2022 May 25. PMID: 35612691
163. Scarinci F, Cacciamani A, Ripandelli G, **Parravano M**. Branch retinal artery occlusion caught in the act by an optical coherence tomography angiography image: case report. *BMC Ophthalmol*. 2022 Jul 14;22(1):303. doi: 10.1186/s12886-022-02517-5. PMID: 35836145
164. Scarinci F, Patacchioli FR, Costanzo E, **Parravano M**. Author Response: Relationship of Choroidal Vasculature and Choriocapillaris Flow With Alterations of Salivary α -Amylase Patterns in Central Serous Chorioretinopathy. *Invest Ophthalmol Vis Sci*. 2022 Jun 1;63(6):10. doi: 10.1167/iovs.63.6.10. PMID: 35679034
165. Fragiotta S, **Parravano M**, Sacconi R, Costanzo E, Viggiano P, Prascina F, Capuano V, Souied EH, Querques G. [A COMMON FINDING IN FOVEAL-SPARING EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN IMPLICATES BASAL LAMINAR DEPOSITS.](#) *Retina*. 2022 Jul 1;42(7):1319-1329. doi: 10.1097/IAE.0000000000003463. PMID: 35696630
166. Iacono P, Da Pozzo S, Bedendo A, Arrigo A, **Parravano M**, Varano M, Battaglia Parodi M. OCT retinal angiography features in patients with rheumatoid arthritis: A pilot study. *Eur J Ophthalmol*. 2022 Jul;32(4):2433-2439. doi: 10.1177/11206721211035626. Epub 2021 Jul 27. PMID: 34313159

167. Sbardella D, Tundo GR, Mecchia A, Palumbo C, Atzori MG, Levati L, Boccaccini A, Caccuri AM, Cascio P, Lacal PM, Graziani G, Varano M, Coletta M, **Parravano M**. [A novel and atypical NF-KB pro-inflammatory program regulated by a CamKII-proteasome axis is involved in the early activation of Muller glia by high glucose.](#) Cell Biosci. 2022 Jul 16;12(1):108. doi: 10.1186/s13578-022-00839-x. PMID: 35842713
168. Scarinci F, **Parravano M**, Patacchioli FR. [Biopsychosocial Illness Model: From the Lung to the Eye.](#) J Clin Med. 2022 Jul 25;11(15):4298. doi: 10.3390/jcm11154298. PMID: 35893389
169. Dunbar HMP, Behning C, Abdirahman A, Higgins BE, Binns AM, Terheyden JH, Zakaria N, Poor S, Finger RP, Leal S, Holz FG, Schmid M, Crabb DP, Rubin GS, Luhmann UFO; MACUSTAR Consortium. Repeatability and Discriminatory Power of Chart-Based Visual Function Tests in Individuals With Age-Related Macular Degeneration: A MACUSTAR Study Report. JAMA Ophthalmol. 2022 Aug 1;140(8):780-789. doi: 10.1001/jamaophthalmol.2022.2113. PMID: 35737401
170. Sacconi R, Forte P, Capuano V, Miere A, Costanzo E, Tombolini B, Fantaguzzi F, Jung C, **Parravano M**, Varano M, Souied E, Bandello F, Querques G. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY CHARACTERIZATION OF EVOLVING LESIONS IN FELLOW EYES OF EXUDATIVE TYPE 3 MACULAR NEOVASCULARIZATION PATIENTS. Retina. 2022 Nov 1;42(11):2075-2082. doi: 10.1097/IAE.0000000000003598. PMID: 35962996
171. Sacconi R, Fragiotta S, Sarraf D, Sadda SR, Freund KB, **Parravano M**, Corradetti G, Cabral D, Capuano V, Miere A, Costanzo E, Bandello F, Souied E, Querques G. Towards a better understanding of non-exudative choroidal and macular neovascularization. Prog Retin Eye Res. 2023 Jan;92:101113. doi: 10.1016/j.preteyeres.2022.101113. Epub 2022 Aug 13. PMID: 35970724 Review.
172. Terheyden JH, Pondorfer SG, Behning C, Berger M, Carlton J, Rowen D, Bouchet C, Poor S, Luhmann UFO, Leal S, Holz FG, Butt T, Brazier JE, Finger RP; MACUSTAR consortium. Disease-specific assessment of Vision Impairment in Low Luminance in age-related macular degeneration - a MACUSTAR study report. Br J Ophthalmol. 2023 Aug;107(8):1144-1150. doi: 10.1136/bjophthalmol-2021-320848. Epub 2022 Mar 30. PMID: 35354561
173. Antonelli G, **Parravano M**, Barbano L, Costanzo E, Bertelli M, Medori MC, Parisi V, Ziccardi L. Multimodal Study of *PRPH2* Gene-Related Retinal Phenotypes. Diagnostics (Basel). 2022 Jul 31;12(8):1851. doi: 10.3390/diagnostics12081851. PMID: 36010202

174. Saßmannshausen M, Behning C, Isselmann B, Schmid M, Finger RP, Holz FG, Schmitz-Valckenberg S, Pfau M; MACUSTAR Consortium, Thiele S. Relative ellipsoid zone reflectivity and its association with disease severity in age-related macular degeneration: a MACUSTAR study report. *Sci Rep.* 2022 Sep 2;12(1):14933. doi: 10.1038/s41598-022-18875-5. PMID: 36056113
175. Fragiotta S, **Parravano M**, Sacconi R, Costanzo E, De Geronimo D, Prascina F, Capuano V, Souied EH, Han IC, Mullins R, Querques G. Sub-retinal pigment epithelium tubules in non-neovascular age-related macular degeneration. *Sci Rep.* 2022 Sep 7;12(1):15198. doi: 10.1038/s41598-022-19193-6. PMID: 36071082
176. **Parravano M**, De Geronimo D, Sacconi R, Giannini D, Costanzo E, Fragiotta S, Viggiano P, Varano M, Querques G. Impact of Intravitreal Anti-VEGF Therapy on Microperimetry of the Retinal Nonperfusion Areas of Patients with Proliferative Diabetic Retinopathy. *Ophthalmol Ther.* 2022 Dec;11(6):2117-2128. doi: 10.1007/s40123-022-00568-x. Epub 2022 Sep 17. PMID: 36114830
177. Viggiano P, Costanzo E, Giannini D, Fragiotta S, De Geronimo D, Giorno P, Picconi F, Frontoni S, Varano M, **Parravano M**. In vivo assessment of associations between photoreceptors structure and macular perfusion in type 1 diabetes. *Br J Ophthalmol.* 2023 Nov;107(11):1672-1679. doi: 10.1136/bjo-2022-321617. Epub 2022 Sep 1. PMID: 36126103
178. Barbano L, Antonelli G, **Parravano M**, Costanzo E, Parisi V, Ziccardi L. Middle-Inner Macular Layers Dysfunction in a Case of Stellate Foveomacular Retinoschisis Detected by Abnormal Multifocal Photopic Negative Response Recordings. *Diagnostics (Basel).* 2022 Nov 10;12(11):2753. doi: 10.3390/diagnostics12112753. PMID: 36359596
179. Costanzo E, Lengyel I, **Parravano M**, Biagini I, Veldsman M, Badhwar A, Betts M, Cherubini A, Llewellyn DJ, Lourida I, MacGillivray T, Rittman T, Tamburin S, Tai XY, Virgili G. Ocular Biomarkers for Alzheimer Disease Dementia: An Umbrella Review of Systematic Reviews and Meta-analyses. *JAMA Ophthalmol.* 2023 Jan 1;141(1):84-91. doi: 10.1001/jamaophthalmol.2022.4845. PMID: 36394831
180. Nikolopoulou E, Sacconi R, Lorusso M, Costanzo E, **Parravano M**, Micelli Ferrari L, Ferrari TM, Querques G. Effect of intravitreal dexamethasone implant in treatment-naïve and previously-treated patients with diabetic macular edema. *Eur J Ophthalmol.* 2022 Dec 1;11206721221143166. doi: 10.1177/11206721221143166. Online ahead of print. PMID: 36457210

181. Servillo A, Zucchiatti I, Sacconi R, **Parravano M**, Querques L, La Rubia P, Prascina F, Bandello F, Querques G. The state-of-the-art pharmacotherapeutic management of neovascular age-related macular degeneration. *Expert Opin Pharmacother*. 2023 Feb;24(2):197-206. doi: 10.1080/14656566.2022.2154145. Epub 2022 Dec 5. PMID: 36469544
182. Ziccardi L, Niceta M, Stellacci E, Ciolfi A, Tatti M, Bruselles A, Mancini C, Barbano L, Cecchetti S, Costanzo E, Cappa M, **Parravano M**, Varano M, Tartaglia M, Cordeddu V. Biallelic Inactivating *TUB* Variants Cause Retinal Ciliopathy Impairing Biogenesis and the Structure of the Primary Cilium. *Int J Mol Sci*. 2022 Nov 24;23(23):14656. doi: 10.3390/ijms232314656. PMID: 36498982
183. Tundo GR, Cascio P, Milardi D, Santoro AM, Graziani G, Lacal PM, Bocedi A, Oddone F, **Parravano M**, Coletta A, Coletta M, Sbardella D. Targeting immunoproteasome in neurodegeneration: A glance to the future. *Pharmacol Ther*. 2023 Jan;241:108329. doi: 10.1016/j.pharmthera.2022.108329. Epub 2022 Dec 14. PMID: 36526014
184. Scarinci F, Patacchioli FR, Costanzo E, **Parravano M**. Cortisol awake response imbalance as an indicator of acute central serous chorioretinopathy: Relationship with choriocapillaris and choroidal features. *Front Med (Lausanne)*. 2022 Nov 30;9:1030352. doi: 10.3389/fmed.2022.1030352. eCollection 2022. PMID: 36530871
185. Garzone D, Terheyden JH, Morelle O, Wintergerst MWM, Saßmannshausen M, Schmitz-Valckenberg S, Pfau M, Thiele S, Poor S, Leal S, Holz FG, Finger RP; MACUSTAR Consortium. Comparability of automated drusen volume measurements in age-related macular degeneration: a MACUSTAR study report. *Sci Rep*. 2022 Dec 19;12(1):21911. doi: 10.1038/s41598-022-26223-w. PMID: 36535990
186. **Parravano M**, Costanzo E, Barbano L, Viggiano P, De Geronimo D, Antonelli G, Parisi V, Varano M, Ziccardi L. Morpho-Functional Macular Assessment in a Case of Facioscapulohumeral Muscular Dystrophy: Photoreceptor Degeneration as Possible Cause for Reduced Visual Acuity over Three Years of Follow-Up. *Diagnostics (Basel)*. 2022 Nov 28;12(12):2977. doi: 10.3390/diagnostics12122977. PMID: 36552982
187. Saßmannshausen M, Behning C, Weinz J, Goerdts L, Terheyden JH, Chang P, Schmid M, Poor SH, Zakaria N, Finger RP, Holz FG, Pfau M, Schmitz-Valckenberg S, Thiele S; MACUSTAR consortium members. Characteristics and Spatial Distribution of Structural Features in Age-Related Macular Degeneration: A MACUSTAR Study

- Report. *Ophthalmol Retina*. 2023 May;7(5):420-430. doi: 10.1016/j.oret.2022.12.007. Epub 2022 Dec 20. PMID: 36563964
188. Sacconi R, Sarraf D, Sadda SR, Freund KB, Servillo A, Fogel Levin MM, Costanzo E, Corradetti G, Cabral D, Zur D, Trivizki O, **Parravano M**, Bandello F, Loewenstein A, Querques G. Nascent geographic atrophy as a predictor of type 3 Macular Neovascularization development. *Ophthalmol Retina*. 2023 Jul;7(7):586-592. doi: 10.1016/j.oret.2023.01.019. Epub 2023 Feb 2. PMID: 36736896
189. Costanzo E, Giannini D, De Geronimo D, Fragiotta S, Varano M, **Parravano M**. Prognostic Imaging Biomarkers in Diabetic Macular Edema Eyes Treated with Intravitreal Dexamethasone Implant. *J Clin Med*. 2023 Feb 6;12(4):1303. doi: 10.3390/jcm12041303. PMID: 36835839
190. Fragiotta S, **Parravano M**, Costanzo E, De Geronimo D, Varano M, Fernández-Avellaneda P, Freund KB. Subretinal Lipid Globules an Early Biomarker of Macular Neovascularization in Eyes with Intermediate Age-Related Macular Degeneration. *Retina*. 2023 Jun 1;43(6):913-922. doi: 10.1097/IAE.0000000000003760. PMID: 36763979
191. Garzone D, Terheyden JH, Morelle O, Wintergerst MWM, Saßmannshausen M, Schmitz-Valckenberg S, Pfau M, Thiele S, Poor S, Leal S, Holz FG, Finger RP; MACUSTAR Consortium. Author Correction: Comparability of automated drusen volume measurements in age-related macular degeneration: a MACUSTAR study report. *Sci Rep*. 2023 Mar 7;13(1):3795. doi: 10.1038/s41598-023-30360-1. PMID: 36882430
192. Lucenteforte E, Finocchietti M, Addis A, Tettamanti M, Varano M, **Parravano M**, Virgili G. Polytherapy and Multimorbidity Pattern of Users of Anti-VEGF Drugs and Dexamethasone for the Treatment of Age-Related Macular Degeneration and other Vascular Retinopathies in Clinical Practice. *Pharmaceuticals (Basel)*. 2023 Apr 25;16(5):646. Doi:10.3390/ph16050646. PMID: 37242429
193. Fragiotta S, Costanzo E, Picconi F, Giorno P, De Geronimo D, Giannini D, Frontoni S, Varano M, **Parravano M**. Progression Biomarkers of Microvascular and Photoreceptor Changes Upon Long-Term Evaluation in Type 1 Diabetes. *Invest Ophthalmol Vis Sci*. 2023 May 1;64(5):23. doi: 10.1167/iops.64.5.23. PMID: 37227747
194. Veritti D, Sarao V, Chhablani J, Loewenstein A, Lanzetta P; Società Italiana della Retina (SIR) Study Group; Intravitreal Injection Setting Study Group (I2SG). The ideal intravitreal injection setting: office, ambulatory surgery room or operating theatre? A narrative review and international survey. *Graefes Arch Clin Exp*

- Ophthalmol. 2023 Nov;261(11):3299-3306. doi: 10.1007/s00417-023-06108-y. Epub 2023 May 18.PMID: 37199802
195. Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; YOSEMITE and RHINE Investigators. Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial. *Jpn J Ophthalmol.* 2023 May;67(3):264-279. doi: 10.1007/s10384-023-00979-8. Epub 2023 Mar 10.PMID: 36897413
196. Sacconi R, Sarraf D, Sadda SR, Freund KB, Servillo A, Fogel Levin MM, Costanzo E, Corradetti G, Cabral D, Zur D, Trivizki O, **Parravano M**, Bandello F, Loewenstein A, Querques G. Nascent Geographic Atrophy as a Predictor of Type 3 Macular Neovascularization Development. *Ophthalmol Retina.* 2023 Jul;7(7):586-592. doi: 10.1016/j.oret.2023.01.019. Epub 2023 Feb 2.PMID: 36736896
197. Virgili G, Curran K, Lucenteforte E, Peto T, **Parravano M**. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. *Cochrane Database Syst Rev* 2023 Jun 27;2023(6):CD007419. doi:10.1002/14651858.CD007419.pub7.PMID: 38275741. Review.
198. Rispoli M, Cennamo G, Antonio LD, Lupidi M, **Parravano M**, Pellegrini M, Veritti D, Vujosevic S, Savastano MC. Practical guidance for imaging biomarkers in exudative age-related macular degeneration . *Surv Ophthalmol.* 2023 Jul-Aug;68(4):615-627. doi: 10.1016/j.survophthal.2023.02.004. Epub 2023 Feb 26.PMID: 36854371 Review.
199. von der Emde L, Mallwitz M, Vaisband M, Hasenauer J, Saßmannshausen M, Terheyden JH; MACUSTAR Consortium; Sloan KR, Schmitz-Valckenberg S, Finger RP, Holz FG, Ach T. Retest variability and patient reliability indices of quantitative fundus autofluorescence in age-related macular degeneration: a MACUSTAR study report. *Sci Rep.* 2023 Oct 13;13(1):17417. doi: 10.1038/s41598-023-43417-y.PMID: 37833348
200. Crincoli E, Servillo A, Catania F, Sacconi R, Mularoni C, Battista M, Querques L, **Parravano M**, Costanzo E, Polito MS, Bandello F, Querques G. Artificial intelligence's role in differentiating the origin for subretinal bleeding in pathologic myopia. *Retina.* 2023 Nov 1;43(11):1881-1889. doi: 10.1097/IAE.0000000000003884.PMID: 37490781
201. Bartolomei F, Costanzo E, **Parravano M**, Hogg RE, Lawrenson JG, Falchini E, Di Simone A, Pastore V, Mastrantuono C, Sato G, Amore F, Biagini I, Ciaffoni GL, Tettamanti M, Virgili G. Use of electronic devices by people attending vision

- rehabilitation services in Italy: A study based on the device and aids registry (D.A.Re). *Eur J Ophthalmol*. 2024 May;34(3):789-796. doi: 10.1177/11206721231200376. Epub 2023 Sep 7. PMID: 37680037
202. Tundo GR, Grasso G, Persico M, Tkachuk O, Bellia F, Bocedi A, Marini S, **Parravano M**, Graziani G, Fattorusso C, Sbardella D. The Insulin-Degrading Enzyme from Structure to Allosteric Modulation: New Perspectives for Drug Design. *Biomolecules*. 2023 Oct 7;13(10):1492. doi: 10.3390/biom13101492. PMID: 37892174.
203. Guymer R, Bailey C, Chaikitmongkol V, Chakravarthy U, Chaudhary V, Finger RP, Gallego-Pinazo R, Chuan AKH, Ishida S, Lövestam-Adrian M, **Parravano M**, Luna Pinto JD, Schmitz-Valckenberg S, Sheth V, Souied EH, Chi GC, Gilberg F, Glittenberg C, Scheidl S, Bengus MR. Rationale and Design of VOYAGER: Long-term Outcomes of Faricimab and Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Clinical Practice. *Ophthalmol Sci*. 2023 Dec 3;4(3):100442. doi: 10.1016/j.xops.2023.100442. eCollection 2024 May-Jun. PMID: 38304609.
204. Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. *Ophthalmology*. 2023 Dec 28:S0161-6420(23)00933-8. doi: 10.1016/j.ophtha.2023.12.026. Online ahead of print. PMID: 38158159
205. Fortini S, Costanzo E, Rellini E, Amore F, Mariotti SP, Varano M, **Parravano M**, Virgili G, Bandello F, Rizzo S, Turco S. Use of the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7) questionnaires for clinical decision-making and psychological referral in ophthalmic care: a multicentre observational study. *BMJ Open*. 2024 Jan 18;14(1):e075141. doi: 10.1136/bmjopen-2023-075141. PMID: 38238181.
206. Servillo A, Kesim C, Sacconi R, Battist M, Capuano V, Fragiotta S, Querques L, **Parravano M**, Souied EH, Bandello F, Querques G. NON-EXUDATIVE INTRARETINAL FLUID IN INTERMEDIATE AGE-RELATED MACULAR DEGENERATION. *Retina*. 2024 Jan 24. doi: 10.1097/IAE.0000000000004054. Online ahead of print. PMID: 38261803.
207. De Geronimo D, **Parravano M**, Sacconi R, Fragiotta S, Giannini D, Costanzo E, Varano M, Querques G. Impact of intravitreal anti-VEGF therapy on intraretinal microvascular abnormalities in proliferative diabetic retinopathy. *Acta Diabetol*. 2024

- Apr;61(4):525-528. doi: 10.1007/s00592-023-02227-4. Epub 2024 Feb 1. PMID: 38302784
208. Rowen D, Carlton J, Terheyden JH, Finger RP, Wickramasekera N, Brazier J; MACUSTAR Consortium. Development and Valuation of a Preference-Weighted Measure in Age-Related Macular Degeneration From the Vision Impairment in Low Luminance Questionnaire-A MACUSTAR Report. *Value Health*. May;27(5):642-654. doi: 10.1016/j.jval.2024.02.001. Epub 2024 Feb 17. PMID: 38369283
209. Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, Heier JS, Holz FG, Iida T, Ives JA, Lim JI, Lin H, Michels S, Quezada Ruiz C, Schmidt-Erfurth U, Silverman D, Singh R, Swaminathan B, Willis JR, Tadayoni R; TENAYA and LUCERNE Investigators. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2. *Ophthalmology*. 2024 Feb 19:S0161-6420(24)00134-9. doi: 10.1016/j.ophtha.2024.02.014. Online ahead of print. PMID: 38382813
210. Sacconi R, Servillo A, Rissotto F, Bottazzi L, Costanzo E, Polito MS, Tombolini B, **Parravano M**, Bandello F, Querques G. Macular Neovascularization Secondary to Subclinical Angioid Streaks in Age-Related Macular Degeneration: Treatment Response to Anti-VEGF at 2-Year Follow-up. *Ophthalmol Ther*. 2024 May;13(5):1211-1222. doi: 10.1007/s40123-024-00918-x. Epub 2024 Mar 7. PMID: 38451452
211. Fragiotta S, Dysli C, **Parravano M**, Sacconi R, Fantaguzzi F, Servillo A, Severo AA, Tombolini B, Costanzo E, De Geronimo D, Capuano V, Souied E, Bandello F, Querques G. Phenotypic characterization of predictors for development and progression of geographic atrophy using optical coherence tomography. *Retina*. 2024 Mar 11. doi: 10.1097/IAE.0000000000004090. Online ahead of print. PMID: 38471039
212. Crincoli E, Catania F, Sacconi R, Ribarich N, Ferrara S, **Parravano M**, Costanzo E, Querques G. Deep learning for automatic prediction of early activation of treatment naïve non-exudative MNVs in AMD. *Retina*. 2024 Mar 14. doi: 10.1097/IAE.0000000000004106. Online ahead of print. PMID: 38489765
213. Calcagno D, Perina ML, Zingale GA, Pandino I, Tuccitto N, Oliveri V, **Parravano MC**, Grasso G. Detection of insulin oligomeric forms by a novel surface plasmon resonance-diffusion coefficient based approach. *Protein Sci*. 2024 Apr;33(4):e4962. doi: 10.1002/pro.4962. PMID: 38501507
214. Servillo A, Sacconi R, Oldoni G, Barlocchi E, Tombolini B, Battista M, Fantaguzzi F, Rissotto F, Mularoni C, **Parravano M**, Zucchiatti I, Querques L, Bandello F,

- Querques G. Advancements in Imaging and Therapeutic Options for Dry Age-Related Macular Degeneration and Geographic Atrophy. *Ophthalmol Ther*. 2024 Aug;13(8):2067-2082. doi: 10.1007/s40123-024-00970-7. Epub 2024 Jun 4
215. **Parravano M**, Cennamo G, Di Antonio L, Grassi MO, Lupidi M, Rispoli M, Savastano MC, Veritti D, Vujosevic S. Multimodal imaging in diabetic retinopathy and macular edema: An update about biomarkers. *Surv Ophthalmol*. 2024 Jun 26:S0039-6257(24)00075-4. doi: 10.1016/j.survophthal.2024.06.006. Online ahead of print.PMID: 38942124 Review.
216. Fragiotta S, **Parravano M**, Corradetti G, Bousquet E, Polito MS, Sacconi R, Capuano V, Costanzo E, Tombolini B, Souied EH, Bandello F, Sadda SR, Sarraf D, Querques G. Vitelliform Lesions Associated with Leptochoroid and Pseudodrusen. *Ophthalmol Retina*. 2024 Jul 14:S2468-6530(24)00326-9. doi: 10.1016/j.oret.2024.07.003. Online ahead of print.PMID: 39004281
217. Fragiotta S, **Parravano M**, Sacconi R, Polito MS, Capuano V, Costanzo E, Tombolini B, Souied EH, Bandello F, Querques G. LeptoVitelliform Maculopathy: delineating a distinct clinical entity from acquired vitelliform lesions. *Eye (Lond)*. 2024 Jul 17. doi: 10.1038/s41433-024-03240-9. Online ahead of print.PMID: 39020047
218. Capuano V, Sacconi R, Miere A, Borrelli E, Amoroso F, Costanzo E, **Parravano M**, Fragiotta S, Bandello F, Souied EH, Querques G. The "triple-layer sign": an optical coherence tomography signature for the detection of non-exudative macular neovascularization. *Graefes Arch Clin Exp Ophthalmol*. 2024 Jul 23. doi: 10.1007/s00417-024-06585-9. Online ahead of print.PMID: 39042148
219. Virgili G, Costanzo E, Biagini I, **Parravano M**, Di Simone A, Amore F, Tettamanti M, Di Pietro S, Ciaffoni GL, Sato G, Giacomelli G, Bartolomei F. Utility values and electronic device use in low-vision people attending rehabilitation services: Data from a nation-wide registry in Italy. *PLoS One*. 2024 Aug 9;19(8):e0308569. doi: 10.1371/journal.pone.0308569. eCollection 2024.PMID: 39121177
220. Stellacci E, Niceta M, Bruselles A, Straface E, Tatti M, Carvetta M, Mancini C, Cecchetti S, **Parravano M**, Barbano L, Varano M, Tartaglia M, Ziccardi L, Cordeddu V. Whole Genome Sequencing Solves an Atypical Form of Bardet-Biedl Syndrome: Identification of Novel Pathogenic Variants of *BBS9*. *Int J Mol Sci*. 2024 Jul 30;25(15):8313. doi: 10.3390/ijms25158313.PMID: 39125883
221. Vujosevic S, Limoli C, Piccoli G, Costanzo E, Marenzi E, Torti E, Giannini D, Polito MS, Luzi L, Nucci P, **Parravano M**. A gender-based analysis of retinal microvascular alterations in patients with diabetes mellitus using OCT angiography. *J Diabetes Complications*. 2024 Aug 28;38(10):108852. doi: 10.1016/j.jdiacomp.2024.108852. Online ahead of print.PMID: 39213716

Books & Book Chapters

Chapter: “Ruolo dei beta bloccanti in oftalmologia”. Oftalmografia n 1/2005.
Manni G, Centofanti M, Cupo G, Oddone F, Parravano M.

Chapter: “La terapia medica: i farmaci che riducono la formazione di umor acqueo”. Il Glaucoma. Ed. Stefano Gandolfi. Mattioli 1885.

Chapter: “Application of Rheopheresis in Ophthalmology” La Dialisi: tecnica e clinica. Ed Società Editrice Universo 2007. C.U. Casciani, V. Cervelli, S. De Angelis, G. Splendiani.

Contribution to the drafting of Italian Guidelines for AMD-Fondazione G.B.Bietti-IRCCS 2008

Chapter: Essential in Ophthalmology, Dr Holz, 2009 title: “OCT vs. photography for diagnosis of diabetic macular edema”; Gianni Virgili, MD, Francesca Menchini, MD, Mariacristina Parravano, MD

Health Technology Assessment of Lucentis in the AMD treatment. JPH-Year 7, Volume 6, Number 2, Suppl. 3, 2009

Contribution to the drafting of management of retinal vein occlusions–IRCCS San Raffaele Milano/Fondazione G.B.Bietti-IRCCS 2010

Chapter: “Disorders of vitreoretinal Interface” Varano M, Parravano M, De Geronimo D. Springer Editor 2014

Chapter:” Role of imaging on diagnosis and treatment of diabetic retinopathy”. Minerva Oftalmologica June 2018, Vol 60 num 2

Chapter:” OCT Angiography in diabetic retinopathy”. Minerva Oftalmologica
2018

Contribution to the book: “Anatomical biomarkers in neovascular AMD”.
Springer Healthcare Italia Srl. 2020

Contribution to the book: “Multimodal imaging in DME. An update on
biomarkers for clinical practice” HPS Health Publishing Service 2022

Contribution to the book: DRCR.net Trials for Diabetic Macular Edema
Parravano, M., Costanzo, E., Sacconi, R., Querques, G. *Diabetic Macular
Edema*, 2023, pp. 69–75

Autorizzazione al trattamento dei dati *ai sensi del Regolamento UE 679/2016 e del D.
Lgs. 196/2003, come novellato dal D. Lgs. 101/2018*



Roma 4 Marzo 2024